<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8069344</article-id><article-id pub-id-type="pmcid-ver">PMC8069344.1</article-id><article-id pub-id-type="pmcaid">8069344</article-id><article-id pub-id-type="pmcaiid">8069344</article-id><article-id pub-id-type="pmid">33918072</article-id><article-id pub-id-type="doi">10.3390/vaccines9040359</article-id><article-id pub-id-type="publisher-id">vaccines-09-00359</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2245-9029</contrib-id><name name-style="western"><surname>Thi</surname><given-names initials="TTH">Thai Thanh Hoang</given-names></name><xref ref-type="aff" rid="af1-vaccines-09-00359">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4285-0332</contrib-id><name name-style="western"><surname>Suys</surname><given-names initials="EJA">Estelle J. A.</given-names></name><xref ref-type="aff" rid="af2-vaccines-09-00359">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JS">Jung Seok</given-names></name><xref ref-type="aff" rid="af3-vaccines-09-00359">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="DH">Dai Hai</given-names></name><xref ref-type="aff" rid="af4-vaccines-09-00359">4</xref><xref ref-type="aff" rid="af5-vaccines-09-00359">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="KD">Ki Dong</given-names></name><xref ref-type="aff" rid="af6-vaccines-09-00359">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9900-2644</contrib-id><name name-style="western"><surname>Truong</surname><given-names initials="NP">Nghia P.</given-names></name><xref ref-type="aff" rid="af2-vaccines-09-00359">2</xref><xref rid="c1-vaccines-09-00359" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Skwarczynski</surname><given-names initials="M">Mariusz</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Toth</surname><given-names initials="I">Istvan</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Tripp</surname><given-names initials="RA">Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-00359"><label>1</label>Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam; <email>hoangthithaithanh@tdtu.edu.vn</email></aff><aff id="af2-vaccines-09-00359"><label>2</label>Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; <email>estelle.suys@monash.edu</email></aff><aff id="af3-vaccines-09-00359"><label>3</label>Biomedical Engineering, Malone Engineering Center 402A, Yale University, 55 Prospect St., New Haven, CT 06511, USA; <email>jungseok.lee78@gmail.com</email></aff><aff id="af4-vaccines-09-00359"><label>4</label>Vietnam Academy of Science and Technology, Graduate University of Science and Technology, Hanoi 100000, Vietnam; <email>nguyendaihai@iams.vast.vn</email></aff><aff id="af5-vaccines-09-00359"><label>5</label>Institute of Applied Materials Science, Vietnam Academy of Science and Technology, 01 TL29 District 12, Ho Chi Minh City 700000, Vietnam</aff><aff id="af6-vaccines-09-00359"><label>6</label>Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea; <email>kdp@ajou.ac.kr</email></aff><author-notes><corresp id="c1-vaccines-09-00359"><label>*</label>Correspondence: <email>nghia.truong@monash.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2021</year></pub-date><volume>9</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">380229</issue-id><elocation-id>359</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2021</year></date><date date-type="accepted"><day>06</day><month>4</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>04</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>26</day><month>04</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-09 06:25:14.833"><day>09</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-00359.pdf"/><abstract><p>COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil<sup>&#174;</sup> and Onpattro<sup>&#174;</sup>, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.</p></abstract><kwd-group><kwd>lipid nanoparticles</kwd><kwd>liposomes</kwd><kwd>vaccines</kwd><kwd>immunotherapy</kwd><kwd>COVID-19</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-00359"><title>1. Introduction</title><p>Nanomedicine is the convergence of nanotechnology, pharmaceutical, and biomedical sciences and has developed rapidly with the design of new nanoformulations for therapeutic purposes, imaging agents and theragnostic applications. Nanoformulation was defined by the Food and Drug Administration (FDA) that is the products in combination with nanoparticles ranging from 1&#8211;100 nanometers (nm); or other formulations outside of this range showing dimension-dependent properties [<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>]. These formulations exhibit many advantages over free drug molecules, possessing an enhanced solubility and improved pharmacokinetics, efficacy, and minimal toxicity [<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>]. More than 50 nanopharmaceuticals have made it to the market consisting of diverse nanoformulations, with lipid nanoparticles being the frontrunner [<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-09-00359" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00359" ref-type="bibr">4</xref>]. Lipid nanoparticles are multicomponent lipid systems typically containing a phospholipid, an ionizable lipid, cholesterol, and a PEGylated lipid [<xref rid="B5-vaccines-09-00359" ref-type="bibr">5</xref>]. The traditional type of lipid nanoparticles is liposomes which was first described in 1961 by the British haematologist, Alec D Bangham [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]. Liposomes were observed under the electron microscope when adding negative stain to dry phospholipids that assembled into spherical shape through a lipid bilayer. Later, in 1980, the first targeted liposomes, modified by active targeting ligands, were developed and led to significantly improve liposome capacity by increasing accumulation at the target tissues/organs/cells without releasing the drug to other sites [<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>]. As a result, the overall efficacy of these liposomes is improved compared to conventional liposomes. Though liposomes have been explored for 30 years as an effective carrier for a variety of drug molecules, it was only in the 1990s that the first Food and Drug Administration (FDA) approval came. This milestone was reached by Doxil<sup>&#174;</sup>, a stealth liposome encapsulating doxorubicin (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>a) and used for the clinical treatment of ovarian and metastatic breast cancer as well as various forms of myeloma [<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>]. Because of the encapsulation of doxorubicin inside PEGylated liposomes, the side effects of free doxorubicin, including chronic cardiomyopathy and congestive heart failure, were significantly mitigated [<xref rid="B8-vaccines-09-00359" ref-type="bibr">8</xref>]. In addition, the PEGylation of liposomes in Doxil<sup>&#174;</sup> supported prolonging the circulation time of this formula after administration [<xref rid="B8-vaccines-09-00359" ref-type="bibr">8</xref>]. Thereafter, the passive accumulation into tumours was achieved. Overall, Doxil<sup>&#174;</sup> has significant cardiotoxicity reduction and high anticancer ability compared to free doxorubicin due to the enhanced permeability and retention effect [<xref rid="B9-vaccines-09-00359" ref-type="bibr">9</xref>].</p><p>The start of the 21st century marks the paradigm-shifting development of multi-component formulations for delivering oligonucleotides for gene therapies [<xref rid="B2-vaccines-09-00359" ref-type="bibr">2</xref>]. These oligonucleotides are macromolecules that exhibit higher therapeutic indexes than conventional chemotherapeutics, especially when the formulation is tailored to reach specific tissues [<xref rid="B10-vaccines-09-00359" ref-type="bibr">10</xref>]. The main challenge gene delivery facing is the instability of naked nucleic acids in physiological media [<xref rid="B11-vaccines-09-00359" ref-type="bibr">11</xref>]. The development of suitable formulations that guarantee sufficient in vivo stability as well as tissue targeting ability has therefore been crucial. This advancement was achieved in 2018, with the FDA approval of Onpattro<sup>&#174;</sup> ((Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA) and Sanofi Genzyme (Cambridge, MA, USA)), consisting of siRNA encapsulated in lipid nano-particles (LNPs) (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>a) for the treatment polyneuropathy in people with hereditary transthyretin-mediated amyloidosis [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-09-00359" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-09-00359" ref-type="bibr">15</xref>]. This LNP is made of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)-butanoate (DLin-MC3-DMA) lipid, disterarolyphosphatidychloline (DSPC), cholesterol and a PEG-lipid (PEG-DMG) that directs the particle in vivo towards the liver hepatocytes [<xref rid="B15-vaccines-09-00359" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-09-00359" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-09-00359" ref-type="bibr">17</xref>]. The ionizable cationic lipid in the LNP complexes with the nucleic acids in acidic media (pH~4) by electrostatic interaction. At physiological pH of 7.4, this formulation becomes neutrally charged and thereby more stealth which dampens the interaction with blood components. Upon internalization of these LNPs in cells, these structural lipids become positively charged, which promotes complexation with the negatively charged endo/lysosomal membrane. This interaction with cellular compartments then disrupts and releases the nucleic acid in the cytosol, where they can exert their effect. Studies have suggested that the structure and pKa of the ionizable lipids play a crucial role in the delivery efficiency of the cargo to the target cells [<xref rid="B5-vaccines-09-00359" ref-type="bibr">5</xref>,<xref rid="B18-vaccines-09-00359" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-09-00359" ref-type="bibr">19</xref>]. For example, Dlin-MC3-DMA, the ionizable lipid in Onpattro (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>b), with a pKa of 6.44, has a 10-fold higher potency than (2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>]-dioxolane, DLin-KC2-DMA) with a pKa of 6.7 [<xref rid="B20-vaccines-09-00359" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-09-00359" ref-type="bibr">21</xref>]. However, it should be noted that subtle differences in the lipid structure can induce variations in the structural packing of LNP&#8217;s, resulting in a different morphology and delivery profile. To improve the particle stability, DSPC, with two saturated acyl chains and a large head group, is incorporated into the formulation (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>b). These lipids produce a cylindrical geometry and play the role of helper lipids in the LNP to maintain the outer layer structure and increase the Onpattro&#8217;s formation [<xref rid="B22-vaccines-09-00359" ref-type="bibr">22</xref>]. The PEG-DMG lipids on the particle surface (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>a,b) prevent particle aggregation due to stealth properties and prolong the circulation time in vivo. Altogether, this LNP system has a solid core structure, a low surface charge at physiological media, and low immunogenicity [<xref rid="B16-vaccines-09-00359" ref-type="bibr">16</xref>]. This technology has sparked interest in further developing genetic therapies and novel delivery systems. Lipid-based nanoparticles are a particularly promising vehicle [<xref rid="B11-vaccines-09-00359" ref-type="bibr">11</xref>,<xref rid="B23-vaccines-09-00359" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-09-00359" ref-type="bibr">24</xref>] for gene delivery with their higher biocompatibility than polymeric and inorganic nanoparticles, their inherent penetrating ability, their biodegradability, structural flexibility, and low immunogenicity [<xref rid="B25-vaccines-09-00359" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>]. These nanostructures can also be produced rapidly at large scale, which is a major advantage when moving into clinical trials and commercial applications [<xref rid="B25-vaccines-09-00359" ref-type="bibr">25</xref>]. </p><p>Since the success of Doxil, Onpattro, and various other LNPs in clinical trials, a myriad of studies has been conducted to translate R&amp;D efforts into commercial products. This review describes the various FDA-approved lipid-based nanoparticles to provide our perspectives on the opportunities and challenges of future developments. Particularly, we first aim to provide an overview of lipid-based nanoparticles and their structure/property relationship. Next, we survey lipid nanoparticles that have been successfully used for cancer drug delivery. We also discuss the more challenging delivery of genetic materials and, finally, its application in preventative vaccines against viruses as well as therapeutic vaccines against cancers, including immunotherapies.</p></sec><sec id="sec2-vaccines-09-00359"><title>2. Lipid-Based Nanoparticles</title><sec id="sec2dot1-vaccines-09-00359"><title>2.1. Overview of Lipid-Based Nanoparticles</title><p>Lipid-based nanoparticles are classified into 5 categories depending on the fabrication method and on the physicochemical properties of the formulations. These are liposomes, niosomes, transfersomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) [<xref rid="B25-vaccines-09-00359" ref-type="bibr">25</xref>]. The main properties of each type of particle are described in <xref ref-type="fig" rid="vaccines-09-00359-f002">Figure 2</xref> and <xref rid="vaccines-09-00359-t001" ref-type="table">Table 1</xref>. In brief, liposomes, structured by phospholipids and cholesterol, have great drug protection and targeting abilities [<xref rid="B27-vaccines-09-00359" ref-type="bibr">27</xref>]. These properties lead to liposomes having reduced toxicity with improved efficacy over free drug in the systemic circulation [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]. The application of liposomes in dermal delivery is limited due to their lack of penetrating ability in the stratum corneum. Additional drawbacks include the poor encapsulation of hydrophilic drugs and the weak storage stability due to drug leakage in the media [<xref rid="B28-vaccines-09-00359" ref-type="bibr">28</xref>]. An alternative to liposomes is niosomes, formed by nonionic surfactants and cholesterol in aqueous conditions, and provide better stability and longer shelf life than their liposomal counterpart [<xref rid="B27-vaccines-09-00359" ref-type="bibr">27</xref>,<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>]. Moreover, their neutral shell exhibits compatibility when compared to positively charged liposomes. Despite their advantageous properties, niosomes also suffer from drug leakage and particle aggregation due to a lack of ionic repulsion, which has been a barrier to grant FDA approvals [<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-09-00359" ref-type="bibr">30</xref>]. Transfersomes are elastic or deformable nanoparticles composed of phospholipids, edge activators (EA) and cholesterol [<xref rid="B28-vaccines-09-00359" ref-type="bibr">28</xref>]. The addition of an EA enhances their flexibility which promotes higher tissue permeation. Transfersomes show the highest penetration capability and entrapment efficiency for lipophilic molecules [<xref rid="B28-vaccines-09-00359" ref-type="bibr">28</xref>]. Their oxidative degradation and high material cost remain a challenge to produce this type of particle in large quantities. All these lipophilic bi/multi-layer nanoparticles with hydrophilic core are able to encapsulate both hydrophilic and hydrophobic drugs without chemical intervention. Hydrophobic drugs are preferentially sandwiched in the external bilayer, while hydrophilic molecules are incorporated in the aqueous cavity (<xref ref-type="fig" rid="vaccines-09-00359-f002">Figure 2</xref>). These particles are therefore considered an effective carrier for a wide spectrum of drugs, with sufficient protection, sustainable drug release, and improved bioavailability.</p><p>The drawbacks related to their limited stability, toxicity, low loading capacity, and convoluted manufacturing has sparked the interest of researchers to develop a new class of particles became [<xref rid="B25-vaccines-09-00359" ref-type="bibr">25</xref>,<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>], mainly aiming at improving the encapsulation efficiency [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>]. Solid lipid nanoparticles (SLNs, <xref ref-type="fig" rid="vaccines-09-00359-f002">Figure 2</xref>) are made of solid fats and surfactants to form a spherical nanoparticle with a solid lipid core and a monolayer shell [<xref rid="B33-vaccines-09-00359" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-09-00359" ref-type="bibr">34</xref>]. They exhibit greater encapsulation efficiency for hydrophobic drugs than liposomes since they lack an aqueous core. This rigid core also improved the stability of SLNs compared to liposomes and polymeric nanoparticles. Indeed, SLNs in aqueous media could be stored for at least 3 years [<xref rid="B35-vaccines-09-00359" ref-type="bibr">35</xref>]. The production of SLNs does not require organic solvents, which eliminates the risk of toxicity caused by solvent residues. Additionally, the large-scale production and excellent reproducibility of SLNs are important properties for downstream commercial and clinical applications [<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>]. Following on SLNs, nanostructured lipid carriers (NLCs) have been developed to enhance drug encapsulation and prevent drug leakage. NLCs are composed of an unstructured lipid interior and a monolayer surfactant periphery (<xref ref-type="fig" rid="vaccines-09-00359-f002">Figure 2</xref>). The core is made of a mixture of solid and liquid lipids that form an imperfect crystal interior to increase the drug loading, while SLNs are saturating the drug loading due to a solid crystal lattice. In addition, this liquid phase in NLC inhibits drug release during storage [<xref rid="B36-vaccines-09-00359" ref-type="bibr">36</xref>].</p><p>Moreover, lipid-polymer hybrid nanoparticles have been studied to create synergies between lipid-based nanoparticles and polymeric particles. Indeed, Zhang et al. made a comparison between lipid-based nanoparticles, polymeric nanoparticles and the hybrid nanoparticles loaded with cisplatin, where the in vivo data suggests that cisplatin-loaded lipid-polymer hybrid nanoparticles inhibited the ovarian carcinoma most effectively [<xref rid="B37-vaccines-09-00359" ref-type="bibr">37</xref>]. Additionally, these hybrid particles have also been considered in gene delivery applications [<xref rid="B24-vaccines-09-00359" ref-type="bibr">24</xref>,<xref rid="B38-vaccines-09-00359" ref-type="bibr">38</xref>]. By optimizing the properties of lipid-based nanoparticles, the safety, encapsulating capacity, stability, pharmacokinetics, bio-distribution, and therapeutic benefit can be controlled as a result [<xref rid="B39-vaccines-09-00359" ref-type="bibr">39</xref>].</p></sec><sec id="sec2dot2-vaccines-09-00359"><title>2.2. The Properties of Lipid-Based Nanoparticles Governing Their Efficiencies</title><p>For the delivery of oligonucleotides, nanoparticles need to encapsulate sufficient amounts of nucleic acid and have specific tissues targeting properties [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>]. Thus, optimization of lipid-based nanoparticle is key for tailoring the delivery to the site of action [<xref rid="B39-vaccines-09-00359" ref-type="bibr">39</xref>]. Structural determinants, such as the particle size, surface charge, PEGylation, and surface modification by targeting ligands have shown to be critical elements in governing the delivery efficiency of these nanoparticles [<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>,<xref rid="B24-vaccines-09-00359" ref-type="bibr">24</xref>,<xref rid="B39-vaccines-09-00359" ref-type="bibr">39</xref>].</p><p>Small size nanoparticles have been shown to facilitate transport in blood and lymphatic capillaries as well as uptake in tissues [<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>,<xref rid="B40-vaccines-09-00359" ref-type="bibr">40</xref>]. More specifically, nanoparticles &lt;10 nm are optimal for diffusion into blood capillaries, whilst particles of 10&#8211;100 nm are favorably uptaken into lymphatic capillaries by convection. When the dimensions are 100&#8211;200 nm their ability to diffuse rapidly is reduced [<xref rid="B40-vaccines-09-00359" ref-type="bibr">40</xref>]. A study by Oussoren et al. demonstrated that 40 nm liposomes had higher lymphatic uptake than larger particles after subcutaneous injection [<xref rid="B41-vaccines-09-00359" ref-type="bibr">41</xref>]. Specifically, 76% of the injected dose of these 40 nm liposomes was taken by the lymph nodes, while larger liposomes remained at the site of subcutaneous injection [<xref rid="B41-vaccines-09-00359" ref-type="bibr">41</xref>]. For liver targeting, after systemic administration, only particles &lt;100 nm, were able to diffuse through the liver fenestrae to reach hepatocytes and hepatic stellate cells [<xref rid="B42-vaccines-09-00359" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-09-00359" ref-type="bibr">43</xref>]. These results indicate that small-sized liposomes enhance lymph node transitivity, and crucially penetrate into liver fenestrae for targeting hepatocytes. For large-sized liposomes (&gt;150 nm), these nanoparticles were taken up by the antigen-presenting cells (APCs) at an injection site, then were carried to the lymph nodes [<xref rid="B44-vaccines-09-00359" ref-type="bibr">44</xref>]. It was demonstrated that they gained a higher cell affinity within the lymph nodes [<xref rid="B44-vaccines-09-00359" ref-type="bibr">44</xref>].</p><p>In the case of the charge effect of lipid-based nanoparticles, this was a hard aspect to reach a general conclusion. Mai et al. reported that an anionic and cationic liposome exhibited significantly higher association with B cells than uncharged liposome within microvascular network [<xref rid="B45-vaccines-09-00359" ref-type="bibr">45</xref>]. This phenomenon was explained by the similar complemental proteins of anionic, cationic liposome shells with those being able to interact with B cells. Cationic liposomes showed the highest levels of interaction and internalization by B cell receptor. Cationic liposomes were in situ decorated with opsonins in blood which is recognized by human immune cells. Anionic liposomes were found to mostly attach on the surface of B cells. This finding suggests that charged liposomes might be suitable for vaccine application, while neutral particles might be more suitable for the delivery of chemotherapies [<xref rid="B45-vaccines-09-00359" ref-type="bibr">45</xref>]. Nakamura et al. found that 30 nm negatively charged LNPs were able to target the lymph node more effectively than positively charged and neutral particles [<xref rid="B40-vaccines-09-00359" ref-type="bibr">40</xref>]. The results showed that 20&#8211;30% of the B220+ cells in the LN were DiD-labelled from the neutral and positively charged LNPs, whereas almost 80% of the B220+ cells were labelled with the negatively charged LNPs [<xref rid="B40-vaccines-09-00359" ref-type="bibr">40</xref>]. Retention of LNPs is at the site of injection was shown to be more pronounced with cationic particles compared to neutral and anionic particles [<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>,<xref rid="B46-vaccines-09-00359" ref-type="bibr">46</xref>]. This effect is due to the high electrostatic interaction between the cationic LNPs and negatively charged tissues. Additionally, cationic LNPs have been reported to bind nonspecifically with plasma proteins and have been linked to higher immunogenicity [<xref rid="B47-vaccines-09-00359" ref-type="bibr">47</xref>]. Taken together, positively charged LNPs have strong cellular affinity but have limited efficacy [<xref rid="B47-vaccines-09-00359" ref-type="bibr">47</xref>], while negatively charged LNPs show to be transported to lymph node effectively. To take advantage of this charge aspect, charge-reversible LNPs have been designed by Hirai et al. to achieve the best of both worlds in gene delivery [<xref rid="B48-vaccines-09-00359" ref-type="bibr">48</xref>]. These LNPs, composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol, and dioleoylglycerophosphate-diethylenediamine conjugate (DOP-DEDA) are positively charged at pH of 6.0, neutral at pH of 7.4 and negatively charged at pH of 8.0. This system is neutral in the bloodstream to minimize degradation by plasma proteins and protect the encapsulated cargo. When circulating in the bloodstream, these DOP-DEDA-LNP vehicles bind to apolipoproteins (e.g., apoE3) at their hydrophobic lipid regions, which promotes their uptake by cancerous cells via both clathrin and caveola-mediated endocytosis pathways. In the endo-lysosomal compartment, the pH is low, which leads to DOP-DEDA-lipid nanoparticles being positively charged for enhanced cytosolic penetration in target cells (<xref ref-type="fig" rid="vaccines-09-00359-f003">Figure 3</xref>) [<xref rid="B48-vaccines-09-00359" ref-type="bibr">48</xref>]. These LNPs with pH-dependent charge-invert properties are thought to be a safe and effective vector to induce RNAi-mediated gene-silencing [<xref rid="B48-vaccines-09-00359" ref-type="bibr">48</xref>]. Another strong determinant for the potency of LNPs is the lipid pKa. A series of studies have shown that a pKa of 6.4 is optimal for maximizing the transfection for siRNA-LNPs [<xref rid="B49-vaccines-09-00359" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-09-00359" ref-type="bibr">50</xref>]. This optimal pKa is also changed in the case of mRNA, with an optimal range of 6.6&#8211;6.8 [<xref rid="B49-vaccines-09-00359" ref-type="bibr">49</xref>].</p><p>As a strategy for improving the targeting capacity, PEGylation of lipid-based nanoparticles has gained much interest in an attempt to reduce the clearance of particles from the bloodstream, and thereby increasing their retention and uptake in tissues into targeting tissues/organs. Studies of Moghimi have revealed that the PEGs modifying anionic liposomes were able to achieve better clearance at the site of subcutaneous administration and higher retention in the lymph nodes compared with bare liposomes. In the case of PEG length, the shorter PEG chains gained lower clearance but higher retention in the lymph nodes compared with the longer PEG modified liposomes [<xref rid="B51-vaccines-09-00359" ref-type="bibr">51</xref>]. Structurally, reports have shown that using a linear or branched PEG chain can significantly dictate the targeting behaviour and transfection ability of LNPs. Truong group synthesized three LNPs with either Tween 80 (2-[2-[3,5-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (E)-octadec-9-enoate), Tween 20 (2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl dodecanoate) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) to encapsulate pDNA and investigate their targeting ability, stability and extent of transfection [<xref rid="B52-vaccines-09-00359" ref-type="bibr">52</xref>]. Tween 20 and Tween 80, both non-ionic surfactants are made of saturated carbon tails with similar branched PEG architecture, compared to the linear structure of DSPE-PEG (<xref ref-type="fig" rid="vaccines-09-00359-f004">Figure 4</xref>). Despite these structural differences, the LNPs exhibited similar stability over a 3-week period. In vivo transfection studies demonstrated that particles with the shorter Tween 20 were able to target the lymph nodes more efficiently. The longer Tween 80, on the other hand, formed LNPs that targeted the spleen but with lower efficiency. LNPs with the linear DSPE-PEG showed predominantly localized transfection at the injection site. Altogether, this study demonstrated that PEGylation of LNPs with branched PEG is a viable approach to target organs with effective transfection selectively [<xref rid="B52-vaccines-09-00359" ref-type="bibr">52</xref>]. It is hypothesized that, aside from the molecular weight and structure, the PEG density on the particle is also an important factor. Across the three types of LNPs, PEGylation of positively charged lipid nanoparticles showed much difference than bare ones [<xref rid="B52-vaccines-09-00359" ref-type="bibr">52</xref>]. PEGylation prevented positively charged lipid nanoparticles from high retention at the site of administration. Whilst PEGylation has been proven useful to prevent premature clearance of particle from the systemic circulation, the production of anti-PEG antibodies has emerged as detrimental co-lateral damage. Recently, efforts have been directed towards alternative strategies with biocompatible polymers to prevent the production of anti-PEG antibodies after the first dose that would otherwise lead to a loss of therapeutic efficacy with potential for adverse effects upon subsequent doses [<xref rid="B53-vaccines-09-00359" ref-type="bibr">53</xref>]. Concurrently, Chen et al. found that incorporation of 4 mol% dexamethasones in lipid-based nanoparticles was able to suppress the immune responses and antibody production after injection [<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>], which might be promising for the development of pegylated lipid nanocarriers.</p><p>Aside from relying on prolonged circulation and passive cellular uptake of nanoparticles, formulation scientists have realized that, by conjugation of a receptor ligand to the particle surface, uptake into target cells could be enhanced. Modification of lipid-based nanoparticles with targeting ligands is a key strategy for efficiently targeting delivery systems into the lymph nodes or other desired tissues/cells. For example, Vu et al. functionalized liposome surface with Hemagglutinin Antigen (HA) to improve antibody production efficiency [<xref rid="B54-vaccines-09-00359" ref-type="bibr">54</xref>]. This work showed that HA-functionalized liposome could cross the barrier cells in the lymph node and enhance germinal center formation and follicular helper T Cell Immunity. Monoclonal antibodies (mAbs) are also a promising avenue for conjugation onto nanoparticle surfaces via covalent bonds for leukocyte targeting [<xref rid="B39-vaccines-09-00359" ref-type="bibr">39</xref>]. Veiga et al. conjugated anti-Ly6C antibodies on lipid-based nanoparticles loaded with siRNA to form the ASSET platform (Anchored Secondary scFv Enabling Targeting) [<xref rid="B55-vaccines-09-00359" ref-type="bibr">55</xref>]. This formulation was able to selectively target inflammatory leukocytes in vivo, as shown in other studies [<xref rid="B56-vaccines-09-00359" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-09-00359" ref-type="bibr">57</xref>]. Similarly, solid tumors often display expressed higher levels of p32 than non-cancerous tissues. To take advantage of this, linTT1 (AKRGARSTA) and LyP-1 peptides have been developed, that can bind to p32 with strong affinity [<xref rid="B58-vaccines-09-00359" ref-type="bibr">58</xref>]. These peptides were therefore utilized as targeting ligand for tumor homing. Indeed, Hunt et al. used linTT1 as targeting ligand in peritoneal carcinomatosis, and found that these nanoparticles could be absorbed to a greater extent than non-targeted particles in peritoneal tumors in mice [<xref rid="B59-vaccines-09-00359" ref-type="bibr">59</xref>]. S&#228;&#228;lik et al. also demonstrated a similar result using linTT1 as a targeting ligand for tumor homing in vitro and in vivo [<xref rid="B58-vaccines-09-00359" ref-type="bibr">58</xref>]. For the treatment of neurological disorder, targeting the nervous system is a requisite. Kuo et al. designed a formulation with amphiphilic solid lipid nanoparticles decorated with the Ln5-P4 (PPFLMLLKGSTR) peptide (Ln5-P4-ASLNs) for co-delivery of nerve growth factor (NGF) and retinoic acid (RA) [<xref rid="B60-vaccines-09-00359" ref-type="bibr">60</xref>]. Ln5-P4 bound the &#945;<sub>3</sub>&#946;<sub>1</sub> integrin and supported cell adhesion and spreading to guide the differentiation of induced pluripotent stem cells toward neurons. This formulation proved to increase the survival rate of induced pluripotent stem cells and the generation of mature neurons as a potential treatment of neurodegenerative diseases and nerve injury in regeneration medicine. In other studies, selectivity for neuronal cells was improved by attachment of the rabies virus glycoprotein (RVG) peptide, a fragment of from the rabies virus glycoprotein, on the surface of siRNA-loaded exosomes [<xref rid="B61-vaccines-09-00359" ref-type="bibr">61</xref>]. This formulation showed positive effects in a mouse model of Alzheimer&#8217;s disease. To enhance the cellular uptake in dendritic cells for enhanced immune response, lipid-based nanoparticles have been conjugated with cell-penetrating peptides such as R8 and GALA [<xref rid="B62-vaccines-09-00359" ref-type="bibr">62</xref>]. Many other ligands of dendritic cell receptors (for review see [<xref rid="B63-vaccines-09-00359" ref-type="bibr">63</xref>]) and of liver cells (for review see [<xref rid="B17-vaccines-09-00359" ref-type="bibr">17</xref>]) have been developed for targeting purposes and are listed below. Fusogenic peptides such as DOPE have also shown to improve membrane fusion, and thus cell uptake [<xref rid="B64-vaccines-09-00359" ref-type="bibr">64</xref>]. Transferrin, folic acid, and antibodies can be used as a ligand for lipid-based nanoparticles to target cancer cell receptors [<xref rid="B65-vaccines-09-00359" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-09-00359" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-09-00359" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-00359" ref-type="bibr">68</xref>]. For the objective of improving siRNA transfection, NP3.47, an inhibitor of the Niemann-Pick type C-1 protein (NPC-1), was conjugated to the surface of the lipid-based nanoparticle. NP3.47 promoted the accumulation of siRNA-LNPs in late endosomes/lysosomes up to 3-fold higher than unmodified lipid-based nanoparticles [<xref rid="B69-vaccines-09-00359" ref-type="bibr">69</xref>]. Due to the increased trapping of NP3.47-LNP-siRNA systems in late endosomes, enhanced opportunities for endosomal escape can be gained from this work for the delivery of siRNA and other oligonucleotide [<xref rid="B69-vaccines-09-00359" ref-type="bibr">69</xref>].</p><p>In recent years, lipid-based nanoparticles have emerged as the most effective carrier for the delivery of cargo to target cells, which have translated into clinical success. The analytical characterization, the basic technological concepts and highlights have been reviewed extensively before [<xref rid="B17-vaccines-09-00359" ref-type="bibr">17</xref>,<xref rid="B38-vaccines-09-00359" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-09-00359" ref-type="bibr">39</xref>,<xref rid="B70-vaccines-09-00359" ref-type="bibr">70</xref>]. The current review will focus on the translation of lipid-based nanoparticles into the clinic.</p></sec></sec><sec id="sec3-vaccines-09-00359"><title>3. Lipid-Based Nanoparticles for Drug Delivery</title><p>For almost 30 years, liposomes have been blossoming in clinical applications. Twenty-one liposomal products have been approved, encapsulating different small molecule drugs. The clinical success of Doxil<sup>&#174;</sup> has given rise to the approval of many new nanodrugs by the FDA, such as Abelcet<sup>&#174;</sup>, AmBisome<sup>&#174;</sup>, DaunoXome<sup>&#174;</sup>, Depocyt<sup>&#174;</sup>, Inflexal V<sup>&#174;</sup>, Myocet<sup>&#174;</sup>, Visudyne<sup>&#174;</sup>, DepoDur<sup>&#174;</sup>, DepoCyt<sup>&#174;</sup>, Marqibo<sup>&#174;</sup>, Mepact<sup>&#174;</sup>, Exparel<sup>&#174;</sup>, Lipodox<sup>&#174;</sup>, Onivyde<sup>&#174;</sup>, Doxorubicin, Nocita<sup>&#174;</sup>, Vyxeos<sup>&#174;</sup>, Shingrix<sup>&#174;</sup>, Lipoplatin<sup>TM</sup>, and Arikayce<sup>&#174;</sup> [<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-09-00359" ref-type="bibr">2</xref>,<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>,<xref rid="B71-vaccines-09-00359" ref-type="bibr">71</xref>]. These formulations are not only used in oncology but also in fungal infections and pain management. Each liposome formulation is described in greater detail in <xref rid="vaccines-09-00359-t002" ref-type="table">Table 2</xref>, with their respective structural lipids shown in <xref ref-type="fig" rid="vaccines-09-00359-f004">Figure 4</xref>. There are four different liposomal products with doxorubicin (Doxil<sup>&#174;</sup>, Myocet<sup>&#174;</sup>, Lipodox<sup>&#174;</sup>, and Liposomal doxorubicin) that are indicated for breast neoplasms. Of these products, Myocet<sup>&#174;</sup> is a conventional formulation, while Doxil<sup>&#174;</sup>, Lipodox<sup>&#174;</sup>, and Doxorubicin are stealth, pegylated liposomes. Aside from these three stealth liposomes, there is only one other product, Onivyde<sup>&#174;</sup> that contains stealth properties by PEGylation. For anaesthetic applications, there are two different liposomes approved that encapsulate bupivacaine. For life-threatening fungal infections, there are also two liposomal formulations on the market that encapsulate amphotericin B. Marqibo<sup>&#174;</sup>, a conventional liposome loaded with vincristine, was approved in 2009 for the treatment of acute lymphoblastic leukaemia and in 2012 for hematologic malignancy and solid tumor treatment. In addition, other drugs including daunorubicin, cytarabine, verteporfin, morphine, mifamurtide, irinotecan, cytarabine, and amikacin were formulated in liposomes. Among them, only Curosurf<sup>&#174;</sup> encapsulated surfactant protein B and C (SP-B and SP-C) in a conventional liposome for the treatment of respiratory distress syndrome (RDS) in premature infants. An atypical formulation is Vyxeos<sup>&#174;</sup>, which has two drugs incorporated into the liposomes, thereby exploiting the synergistic effect of daunorubicin and cytarabine to treat acute myeloid leukaemia more effectively. In summary, within this period, there were 13 chemotherapeutics and one protein formulated in conventional and stealth liposomes successfully commercialized.</p><p>Aside from those formulations, there are many other liposomes indicated for chemotherapy in currently in clinical trials (<xref rid="vaccines-09-00359-t003" ref-type="table">Table 3</xref>). MBP-426<sup>&#174;</sup> of Mebiopharm Co., Ltd. (Tokyo, Japan) is an oxaliplatin-encapsulated transferrin-conjugated N-glutaryl phosphatidylethanolamine-liposome and is indicated for gastric, oesophageal and gastro-oesophageal adenocarcinoma. The phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00355888">NCT00355888</ext-link>) of MBP-426<sup>&#174;</sup> was completed [<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>], with phase IIa/b starting (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00964080">NCT00964080</ext-link>) for characterization of the safety profile in combination with leucovorin and fluorouracil. Mebiopharm Co., Ltd. has also developed other products including MBP-Y003, MBP-Y004, and MBP-Y005 in preclinical stages which are transferrin-conjugated liposomes loaded with methotrexate, docetaxel, and gemcitabine, respectively [<xref rid="B73-vaccines-09-00359" ref-type="bibr">73</xref>]. These four products are designed with a transferrin ligand for targeting receptors that are overexpressed in cancerous tissues.</p><p>ThermoDox<sup>&#174;</sup> of Celsion is a heat-sensitive liposome loaded with doxorubicin for the treatment of hepatocellular carcinoma. The thermosensitive lipid is able to change structure at 40&#8211;45 &#176;C to release doxorubicin rapidly in the tumor through radiofrequency ablation. Although four commercialized liposomes loading doxorubicin were already launched into the market successfully, ThermoDox<sup>&#174;</sup> is a new product with advanced characteristics, that showed a 5-fold release in doxorubicin concentration at the tumor site when compared to Doxil<sup>&#174;</sup> [<xref rid="B74-vaccines-09-00359" ref-type="bibr">74</xref>]. Phase III clinical trials of ThermoDox<sup>&#174;</sup> in combination with standardized radiofrequency ablation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02112656">NCT02112656</ext-link>) have been completed [<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>,<xref rid="B74-vaccines-09-00359" ref-type="bibr">74</xref>].</p><p>MM-302 of Merrimack Pharmaceuticals, is a stealth liposome modified with antibodies targeting the human epidermal growth factor receptor 2 (HER2) and loaded with doxorubicin [<xref rid="B75-vaccines-09-00359" ref-type="bibr">75</xref>], which has applied for phase 1 clinical trial in 2011. MM-302 aimed at overcoming the limitations of doxorubicin related to cardiac toxicity and to the ineffective targeting of cancerous cells. MM-302 was assessed in combination with trastuzumab or trastuzumab plus cyclophosphamide to treat advanced HER2-positive breast cancer. The promising data of phase 1 clinical trials inspired MM-302 to move to phase 2. However, the efficacy results did not show significant benefit compared to comparator treatments, which led to Merrimack discontinuing further trials with MM-302 in 2016 [<xref rid="B76-vaccines-09-00359" ref-type="bibr">76</xref>]. </p><p>SPI-77 developed by Sequus Pharmaceuticals (Johnson &amp; Johnson) is a cisplatin-encapsulated stealth liposome, developed for the treatment of recurrent ovarian cancer [<xref rid="B77-vaccines-09-00359" ref-type="bibr">77</xref>] and stage IV non-small cell lung cancer (NSCLC) [<xref rid="B78-vaccines-09-00359" ref-type="bibr">78</xref>]. SPI-77 is hypothesized to mitigate the systemic toxicity of cisplatin and to achieve a high delivery capacity. However, due to lack of significant data, in phase 1 and phase 2 clinical trials, the manufacturer decided to halt further trials [<xref rid="B77-vaccines-09-00359" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-09-00359" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-09-00359" ref-type="bibr">79</xref>]. </p><p>The liposome-encapsulated mitoxantrone (LEM) from INSYS Therapeutics Inc is made of lyophilized lipids mixed with mitoxantrone salt (under the commercial name of Novantrone). This formulation was generated to improve the safety and efficacy of free Novantrone. LEM entered phase 1 clinical trials in 2001 with an identifier of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00024492">NCT00024492</ext-link>. Patients with advanced solid tumors (40 participants) were recruited for intravenous injection of LEM. The results from the blood pharmacokinetics and tumor observation were completed in 2004, but no results were posted.</p><p>OSI-211, a liposome encapsulating lurtotecan, was developed for treatment of recurrent small-cell lung cancer. OSI-211 was clinically tested (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00046787">NCT00046787</ext-link>) by Astellas Pharma Inc. (Chuo City, Tokyo, Japan) The University of Pittsburgh and ALZA company developed S-CKD602 and completed phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00177281">NCT00177281</ext-link>) to determine the maximum tolerated dose as well as the safety in patients with advanced tumors. S-CKD602 is a PEGylated liposome encapsulating CKD-602, a camptothecin analogue inhibiting topoisomerase I, with liposomal formulation consisting of N-(carbonyl-methoxypolyethylene glycol 2000)-DSPE and DSPC [<xref rid="B80-vaccines-09-00359" ref-type="bibr">80</xref>]. Another liposome named LEP-ETU also entered phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00080418">NCT00080418</ext-link>). LEP-ETU is a liposome formed by DOPC, cholesterol and cardiolipin that encapsulates paclitaxel to treat ovarian, breast and lung cancers [<xref rid="B81-vaccines-09-00359" ref-type="bibr">81</xref>]. Topotecan Liposomes Injection (TLI) also entered Phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00765973">NCT00765973</ext-link>) to test its safety and efficacy. Up till now, these four products have completed their clinical trial phase, but no updated information has been released.</p><p>Three products, including LiPlaCis, INX-0076 and TLD-1 have been in progress of clinical trials. INX-0076 was formulated into a liposome with topotecan for advanced solid tumors. LiPlaCis, developed for treatment of advanced solid tumours, is a liposomal formulation, incorporating cisplatin, which is composed of lipids with degradation properties controlled by the sPLA2 enzyme for a tumour-triggered release mechanism [<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]. TLD-1 is a novel liposome encapsulating doxorubicin, indicated for advanced solid tumors [<xref rid="B83-vaccines-09-00359" ref-type="bibr">83</xref>].</p></sec><sec id="sec4-vaccines-09-00359"><title>4. Lipid-Based Nanoparticles for Gene Therapy</title><p>Recently, nucleic acid therapeutics, such as small interfering RNAs (siRNA), small activating RNAs (saRNA), and messenger RNA (mRNA), have gained much traction and have been at the forefront of medicine with their potential in delivery efficiency and treatment of a wide range of diseases [<xref rid="B87-vaccines-09-00359" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-09-00359" ref-type="bibr">88</xref>]. However, these genetic drugs are prone to rapid degradation by serum endonucleases. To protect them, liposomes or lipid nanoparticles (LNPs, including SLNs and/or NLCs) have been increasingly utilized as a delivery system which have sufficient encapsulating capacity and which are capable of targeting tissues and cells [<xref rid="B89-vaccines-09-00359" ref-type="bibr">89</xref>]. A series of ionizable lipids have been designed for gene delivery, each with their own pKa and structural properties, such as 1,2-dioleoyl-3-dimethylaminopropane (DODAP, pKa of 6.6), 1,2-dilinoleoyl-3-dimethylaminopropane, 1,2- dilinoleyloxy-3-dimethylaminopropane (DLin-DMA, pKa of 6.8), 2,2-dilinoleyl- 4-dimethylaminomethyl-[<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>]-dioxolane (DLin-K-DMA, pKa of 5.94), 2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>]-dioxolane (DLin-KC2-DMA, pKa of 6.68) (<xref ref-type="fig" rid="vaccines-09-00359-f005">Figure 5</xref>) [<xref rid="B18-vaccines-09-00359" ref-type="bibr">18</xref>], and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)-butanoate (Dlin-MC3-DMA, pKa of 6.44) (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>). Aside from the pKa value, the linker between the head group and alkyl chains is also a determinant for delivery efficiency. The ketal linker was demonstrated to be the best candidates when compared to ester- and alkoxy-linkers [<xref rid="B18-vaccines-09-00359" ref-type="bibr">18</xref>]. Dlin-K-DMA with significant in vivo silencing of factor VII was compared to other lipids without ketal linkers [<xref rid="B18-vaccines-09-00359" ref-type="bibr">18</xref>]. A series of linker optimization, resulted in DLin-MC3-DMA, which is now considered as a promising candidate for genetic drug delivery and able to launch in the clinic. Dlin-MC3-DMA exhibited a 10-fold higher potency than Dlin-KC2-DMA for hepatic gene silencing in vivo [<xref rid="B21-vaccines-09-00359" ref-type="bibr">21</xref>]. An illustration of this lipid&#8217;s potency is provided with Onpattro<sup>&#174;</sup> (<xref ref-type="fig" rid="vaccines-09-00359-f001">Figure 1</xref>). The second siRNA therapeutic to receive FDA approval was GIVLAARI<sup>TM</sup> (givosiran, ALN-AS1) in November 2019 [<xref rid="B90-vaccines-09-00359" ref-type="bibr">90</xref>] and a market authorization from the European Committee&#8212;a synthetic siRNA targeting the ALAS1 gene in hepatocytes. This therapy is prescribed for adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme. This RNA therapy, however, is composed naked nucleotide-modified siRNA without a carrier, but in the presence of a targeting ligand that directs the drug towards the liver.</p><p>An LNP platform developed by Arcturus Therapeutics, Inc. (San Diego, CA, USA) for RNA delivery was named as lipid-enabled and unlocked nucleomonomer agent modified RNA (LUNAR<sup>&#174;</sup>). LUNAR is made of a proprietary ionizable amino lipids (58 molar %, ATX, <xref ref-type="fig" rid="vaccines-09-00359-f004">Figure 4</xref>), a phospholipid 1,2-distearoyl-sn-glycero-3-phosphocholine (7 molar %, DSPC), cholesterol (33.5 molar %) and DMG-PEG<sub>2000</sub> (1.5 molar %) [<xref rid="B91-vaccines-09-00359" ref-type="bibr">91</xref>]. The ATX lipids are similar to a lipid family developed by Alnylam/Acuitas that can be modified to target specific cells type or tissues for a variety of indications. Unlike the conventional cationic lipids, the ATX lipids are degraded under physiological conditions through the breaking of the ester linkages, thereby facilitating rapid degradation for faster metabolism and better safety profile [<xref rid="B92-vaccines-09-00359" ref-type="bibr">92</xref>]. It was shown that LUNAR was employed to encapsulate the human FIX (hFIX) mRNA for treatment of hemophilia B in a preclinical setting [<xref rid="B93-vaccines-09-00359" ref-type="bibr">93</xref>]. The efficacy of LUNAR in mRNA delivery was 5-fold higher than other lipid carriers with DLin-MC3-DMA or heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate) (MC3). Additionally, the LUNAR formulation did not elicit an adverse immune response, such as an increase of liver enzymes that are markers for acute liver toxicity [<xref rid="B93-vaccines-09-00359" ref-type="bibr">93</xref>]. </p><p>Aside from Onpattro as the first commercial RNA product, GIVLAARI<sup>TM</sup> and mRNA-LUNAR in preclinical studies, a variety of RNA-LNP have now entered clinical trials (<xref rid="vaccines-09-00359-t004" ref-type="table">Table 4</xref>). TKM-080301 was studied and produced by Arbutus Biopharma Corporation for the treatment of solid tumors, such as gastrointestinal neuroendocrine tumors or adrenocortical carcinoma (ACC) [<xref rid="B94-vaccines-09-00359" ref-type="bibr">94</xref>]. TKM-080301 is composed of a siRNA encapsulated in LNPs that can target polo-like kinase 1 (PLK1), which regulates critical aspects of tumor progression. A phase I/II clinical study was conducted (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01262235">NCT01262235</ext-link>) with promising safety and anti-tumor efficacy data [<xref rid="B94-vaccines-09-00359" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-09-00359" ref-type="bibr">95</xref>]. After testing on 16 patients at 0.6 or 0.75 mg/kg/week for 18 cycles, it was confirmed that TKM-080301 could increase PLK1 expression and inactivate the target in ACC. Later, in 2018, TKM-080301 was clinically evaluated for safety, pharmacokinetics and preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02191878">NCT02191878</ext-link>) [<xref rid="B96-vaccines-09-00359" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-09-00359" ref-type="bibr">97</xref>]. In this early-phase study with 43 patients, the antitumor effect of TKM-080301 was limited. Consequently, TKM-080301 did not continue for further evaluation as a single agent for the treatment of HCC, and clinical studies have been terminated [<xref rid="B97-vaccines-09-00359" ref-type="bibr">97</xref>].</p><p>Dicerna Pharmaceuticals (Lexington, Massachusetts MA, USA), a company specializing in RNA medicines that silence genes has developed DCR-MYC, a lipid particle that incorporates synthetic double-stranded RNA to target the MYC oncogene and suppress cancer progression [<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>,<xref rid="B98-vaccines-09-00359" ref-type="bibr">98</xref>]. This therapy has been evaluated in a dose escalation study in patients with multiple myeloma, lymphoma or solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02110563">NCT02110563</ext-link>). Additionally, DCR-MYC was also evaluated in clinical trials for hepatocellular carcinoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02314052">NCT02314052</ext-link>) [<xref rid="B99-vaccines-09-00359" ref-type="bibr">99</xref>]. However, all clinical studies related to DCR-MYC have been stopped by Dicerna, as the early efficacy results did not meet the company&#8217;s expectations to warrant further development [<xref rid="B99-vaccines-09-00359" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-09-00359" ref-type="bibr">100</xref>].</p><p>In the line of using genetic therapies for cancer applications, Wagner et al. developed a nanoliposomal EphA2-targeted therapeutic (EphA2 siRNA), which has a neutral charge and is aimed at reducing organ toxicity associated with charged particles [<xref rid="B101-vaccines-09-00359" ref-type="bibr">101</xref>]. EphA2 belongs to a subfamily of the tyrosine kinase receptors, and is overexpressed in breast, lung, prostate, ovarian, pancreatic, and endometrial cancer [<xref rid="B101-vaccines-09-00359" ref-type="bibr">101</xref>]. The encapsulated siRNA therefore disturbs the cancer cell proliferation and slows down tumor growth. In preclinical studies, this formulation exhibited a significant anti-cancer effect with mild responses of hemolytic reaction, inflammation and mononuclear cell infiltration in gastrointestinal tract, heart and kidney [<xref rid="B102-vaccines-09-00359" ref-type="bibr">102</xref>]. These promising results have led EphA2 siRNA to entering phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01591356">NCT01591356</ext-link>), where it will be used in patients with advanced or recurrent solid tumors [<xref rid="B103-vaccines-09-00359" ref-type="bibr">103</xref>].</p><p>ModernaTX, Inc. and AstraZeneca have developed the mRNA-2752 encapsulated LNP and have applied for a phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link>). This mRNA encodes for OX40L, a T-cell co-stimulator, IL-23 and IL-36&#947; pro-inflammatory cytokines. Patients with solid tumors were treated individually with mRNA-2752 or in combination with durvalumab. Tumor shrinkage in monotherapy or dual-therapy with durvalumab was observed in pre-clinical studies in patients with advanced solid malignancy or lymphoma, which supports the move of mRNA-2752 towards phase 1 studies. Using similar technology, ModernaTX, Inc. studied another LNP candidate (mRNA 2416) for treatment of patients with advanced malignancies [<xref rid="B110-vaccines-09-00359" ref-type="bibr">110</xref>]. mRNA-2416 is delivered directly to tumors that over-express OX40 which then activate strongly T cell responses that kill the tumor. Currently, this candidate has been recruiting for phase 1&#8211;2 clinical trials with identifier of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03323398">NCT03323398</ext-link> [<xref rid="B110-vaccines-09-00359" ref-type="bibr">110</xref>].</p><p>Alnylam Pharmaceuticals also completed a Phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01158079">NCT01158079</ext-link>) for ALN-VSP02 in 2012 [<xref rid="B107-vaccines-09-00359" ref-type="bibr">107</xref>], which is an LNP with siRNA that targets the expression of vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) [<xref rid="B106-vaccines-09-00359" ref-type="bibr">106</xref>]. These factors are overexpressed in many tumors and contribute to tumor proliferation and survival. Therefore, ALN-VSP02 silences these two mRNAs and prevents the translation of the KSP and VEGF proteins, which inhibits tumor growth in these patients. </p><p>The LNP-RNA system has proven to be a versatile platform with uses beyond cancer treatments. From 2009 to 2019, there were 6 similar products approved for clinical trials (<xref rid="vaccines-09-00359-t004" ref-type="table">Table 4</xref>). Arbutus Biopharma Corporation completed phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02631096">NCT02631096</ext-link>) for ARB-001467 [<xref rid="B17-vaccines-09-00359" ref-type="bibr">17</xref>]. This formula contained siRNAs against the four hepatitis B virus transcripts and was indicated for patients with hepatitis B. Bristol-Myers Squibb and Nitto Denko Corporation completed a phase 1b/2 clinical trial of ND-L02-s0201, which was indicated for patients with moderate to extensive hepatic fibrosis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02227459">NCT02227459</ext-link>). ND-L02-s0201, a heat shock protein 47 siRNA, moderates collagen synthesis and secretion to prevent the fibrosis. This clinical study has started in Japan after being initiated in Europe and the United States. Arrowhead Research had also generated the ARC-520 to treat hepatitis B virus and applied phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02065336">NCT02065336</ext-link>). ARC-520 formulated from interference RNA, which can reduce all RNA transcripts derived from covalently closed circular DNA that leads to reduce viral antigens and hepatitis B virus DNA. However, ARC-520 was terminated due to delivery-associated toxicity [<xref rid="B112-vaccines-09-00359" ref-type="bibr">112</xref>]. Currently, Dicerna Pharmaceuticals, Inc. has developed LNPs with siRNA (named as DCR-HBVS) targeting the mRNA for the hepatitis B surface antigen (HbsAg) for treatment of chronic hepatitis B. Phase 1 clinical trial for DCR-HBVS has been requested (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03772249">NCT03772249</ext-link>) when promising preclinical data was obtained, in which a mouse model of hepatitis B, treated by DCR-HBVS was significantly reduced.</p><p>Alnylam Pharmaceuticals also completed a phase 1 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01437059">NCT01437059</ext-link>) for ALN-PCS02 for the treatment of patients with hypercholesterolemia. ALN-PCS02 is formulated from siRNA encapsulated in lipid LNPs, in which siRNA reduces the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme of plasma cholesterol metabolism leading to lower levels of low-density lipoprotein [<xref rid="B102-vaccines-09-00359" ref-type="bibr">102</xref>].</p><p>Tekmira registered a phase 1 clinical trial with identifier of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00927459">NCT00927459</ext-link> for PRO-040201 in 2009, which contains siRNA loaded in a stable nucleic acid LNP. PRO-040201 can target ApoB produced by hepatocytes to control the level of cholesterol in blood. Although the preliminary clinical trial demonstrated that PRO-040201 delivered siRNA effectively to liver and reduce significantly low density lipoprotein, there were flu-like symptoms at the highest dose [<xref rid="B102-vaccines-09-00359" ref-type="bibr">102</xref>]. Thus, Tekmira decided to terminate the study in 2010.</p></sec><sec id="sec5-vaccines-09-00359"><title>5. Lipid-Based Nanoparticles for Vaccines</title><p>At the ending of 2019, Wuhan city, Hubei province of China appeared pneumonia patients. After that, in January 2020, a novel coronavirus causing pneumonia was confirmed by Chinese under the name of 2019 nCoV. World Health Organization (WHO), Chinese authorities and other partners have worked to understanding about properties, sources, prevention of virus spread, and treatments [<xref rid="B113-vaccines-09-00359" ref-type="bibr">113</xref>]. However, COVID-19 pandemic is spreading all over the world unprecedentedly that impacts on global economy individual and community health seriously. As a result, urgent demand is not only to save COVID-19 patients but also to develop vaccines.</p><p>Nucleic acid-based vaccines have gained much attention and the first candidates have entered clinical trials [<xref rid="B114-vaccines-09-00359" ref-type="bibr">114</xref>]. Nucleic acid vaccines possess many advantages over conventional protein-based vaccines such as ease of synthesis, safety, effective antigen manipulation, cost, and scale-up ability [<xref rid="B115-vaccines-09-00359" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-09-00359" ref-type="bibr">116</xref>]. However, nucleic acids display some inherent disadvantages [<xref rid="B114-vaccines-09-00359" ref-type="bibr">114</xref>,<xref rid="B116-vaccines-09-00359" ref-type="bibr">116</xref>]. DNA has low immunogenicity and might integrate with human genome [<xref rid="B116-vaccines-09-00359" ref-type="bibr">116</xref>]. RNA is rapidly degraded in physiological media and efficiently excreted by glomerular filtration within less than 10 min [<xref rid="B14-vaccines-09-00359" ref-type="bibr">14</xref>]. In spite of that, RNA is still considered the best platform technology for developing vaccines against various diseases, both non-infectious diseases and infectious [<xref rid="B117-vaccines-09-00359" ref-type="bibr">117</xref>]. In vitro transcribed RNA vaccines exhibit efficient antigen expression and self-adjuvancy [<xref rid="B118-vaccines-09-00359" ref-type="bibr">118</xref>]. Adjuvants are often added to vaccines in order to enhance and prolong the immune response [<xref rid="B119-vaccines-09-00359" ref-type="bibr">119</xref>], but they also have the potential to cause inflammatory side effects [<xref rid="B120-vaccines-09-00359" ref-type="bibr">120</xref>]. Therefore, RNA vaccines are becoming a promising candidate as self-adjuvant vaccines with minimal inflammatory side effects [<xref rid="B121-vaccines-09-00359" ref-type="bibr">121</xref>]. Particles for vaccine delivery have to achieve a high loading capacity, sustainable release, no leakage, and simple manufacturing [<xref rid="B122-vaccines-09-00359" ref-type="bibr">122</xref>]. To maximize the efficacy of those vaccine candidates as well as to achieve a favourable index for human applications, scaffolds carrying those agents play an important role in vaccine efficacy. Careful consideration of appropriate scaffolds for a specific vaccine plays a key role in vaccine fabrication. Related to liposome scaffolds, four other approved liposomes Inflexal V, Epaxal, Mosquirix and Shingrix were commercialized successfully as vaccines [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>,<xref rid="B71-vaccines-09-00359" ref-type="bibr">71</xref>]. Those liposomes are incorporating virosomal influenza vaccine, inactivated hepatitis A virus, RTS,S antigen-based vaccine, and glycoprotein E based vaccine [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>]. LNPs have become ideal candidates for vaccine design, they are similar to viral structures with virus-like dimensions, and able to carry antigens and adjuvants [<xref rid="B123-vaccines-09-00359" ref-type="bibr">123</xref>]. </p><p>Along with the history of vaccine development, adjuvants are equally as important and have led to significant advances in vaccine formulations and efficacy thereof. Especially Alum (insoluble aluminium salts) is incorporated in many childhood vaccines such as DTaP (diphtheria, tetanus, pertussis) vaccines, the pneumococcal conjugate vaccine, and hepatitis B vaccines [<xref rid="B124-vaccines-09-00359" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-09-00359" ref-type="bibr">125</xref>]. Of other approved vaccines in 2015, there were many formulations that included adjuvants. For example, AS01 (MPL (a naturally derived TLR4 ligand)and QS21 saponin), MF59, and immunostimulatory oligonucleotides are presented in Shingrix, Fluad and Heplisav, respectively [<xref rid="B124-vaccines-09-00359" ref-type="bibr">124</xref>]. Besides, various other vaccine adjuvants including AS04, RC-529, CpG ODN, TLR9 agonist, TLR4 agonist, and virosomes have been included in licensed products [<xref rid="B124-vaccines-09-00359" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-09-00359" ref-type="bibr">125</xref>]. Those vaccines confirm that incorporation of adjuvants can progress the vaccine into the clinic more rapidly and successfully. Also, a broad range of lipids has been reported to possess the strong adjuvant activity. Especially, cationic lipid, dimethyldioctadecylammonium bromide (DDA), showed the deposition of the antigen at the injection site, the enhancement of a cellular antigen internalization, and an antigen association [<xref rid="B126-vaccines-09-00359" ref-type="bibr">126</xref>]. As a result, LNPs made from DDA were forecasted to possess self-adjuvant activity. Indeed, Anderluzzi et al. reported that an emulsion of polymeric nanoparticles, liposomes, and solid lipid nanoparticles structured by DDA gained high antigen adsorption efficiency, in vitro antigen trafficking, in vivo distribution and high antibody response [<xref rid="B126-vaccines-09-00359" ref-type="bibr">126</xref>]. However, the immunogenicity level was strongly dependent on the type of formulation. The nanoparticle system exhibited high cell uptake and antigen processing, while the emulsion showed high antibody responses [<xref rid="B126-vaccines-09-00359" ref-type="bibr">126</xref>]. </p><p>In another case, LNPs were used as a carrier system for adjuvants and mRNA to achieve their synergistic effects in immune stimulation. Lee et al. fabricated the LNPs with an adjuvant of Pam3 (tri-palmitoyl-S-glyceryl cysteine linked to the penta- peptide) to carry mRNA for cancer immunotherapy. Their results indicated that this formulation triggered different TLR&#8217;s to increase the population of CD8+ T cells, thereby preventing tumor growth. So the combination of an adjuvant and mRNA in an LNP carrier could be a promising avenue in mRNA-based cancer therapeutics [<xref rid="B118-vaccines-09-00359" ref-type="bibr">118</xref>].</p><sec id="sec5dot1-vaccines-09-00359"><title>5.1. Lipid-Based Nanoparticles for Therapeutic Vaccines</title><p>LNPs and liposomes showed their best suitability for RNA-based vaccines in protective ability, pharmacokinetics, tissue distribution and targeted delivery (dendritic cells and macrophages) [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B114-vaccines-09-00359" ref-type="bibr">114</xref>,<xref rid="B122-vaccines-09-00359" ref-type="bibr">122</xref>,<xref rid="B127-vaccines-09-00359" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-09-00359" ref-type="bibr">128</xref>]. With optimization of over 1000 candidates, it was concluded that LNPs are suitable delivery vehicles for mRNA coding antigens for anti-cancerous vaccines [<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>]. Such an RNA-LNPs have been designed to reverse M2-like macrophages or other immunosuppressive phenotypes, to activate the innate immunity, to inhibit other soluble immunosuppressive factors, and to induce tumor-infiltrating lymphocytes for immunomodulation strategies to treat malignant tumors (<xref ref-type="fig" rid="vaccines-09-00359-f006">Figure 6</xref>). In fact, there are a lot of studies related to this topic that have been summarized in the selected reviews [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-09-00359" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-09-00359" ref-type="bibr">14</xref>]. Herein, we will focus on the clinical trials of developed vaccines, summarized in <xref rid="vaccines-09-00359-t005" ref-type="table">Table 5</xref>.</p><p>Lipo-MERIT is a cancer vaccine [<xref rid="B133-vaccines-09-00359" ref-type="bibr">133</xref>] that is made of four mRNA&#8217;s encoding for NY-ESO-1, MAGE-A3, tyrosinase and TPTE which are encapsulated in liposomes without any modification with molecular ligands [<xref rid="B134-vaccines-09-00359" ref-type="bibr">134</xref>]. Lipo-MERIT travels to spleen and is taken up by splenic dendritic cells and macrophages to activate NK, B, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells. For the progress of commercial preparation, Lipo-MERIT is currently in Phase 1 clinical trials [<xref rid="B130-vaccines-09-00359" ref-type="bibr">130</xref>].</p><p>Another cancer vaccine in clinical trials is the mRNA-LNP personalized cancer vaccine, mRNA-4157, developed by ModernaTX, Inc. and Merck Sharp &amp; Dohme Corp. This vaccine is indicated for patients with resected solid tumors including bladder carcinoma, melanoma and non-small cell lung carcinoma (NSCLC). In addition, mRNA-4157 is also used in combination with pembrolizumab for patients with advanced or metastatic cancers. After administration, this LNP is uptaken and translated by antigen presenting cells, thereby inducing both cytotoxic T-lymphocyte and memory T-cell-dependent immune responses to destroy the cancer cells. Currently, mRNA-4157 is being clinically evaluated for safety and efficacy in Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03313778">NCT03313778</ext-link>) [<xref rid="B131-vaccines-09-00359" ref-type="bibr">131</xref>] and Phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03897881">NCT03897881</ext-link>) [<xref rid="B132-vaccines-09-00359" ref-type="bibr">132</xref>].</p><p>Stimuvax (L-BLP-25, BLP25 liposome) of EMD Serono &amp; Merck KgaA, Darmstadt, Germany was also entered phase 3 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00409188">NCT00409188</ext-link>). This therapeutic vaccine provides immunity to kill the cancer cells expressing a glycoprotein antigen of Mucin 1 (MUC-1). The trial for patients with advanced non-small cell lung cancer (NSCLC), but the results were disappointing and did not meet the primary endpoint [<xref rid="B135-vaccines-09-00359" ref-type="bibr">135</xref>]. As a result, L-BLP-25 was terminated.</p></sec><sec id="sec5dot2-vaccines-09-00359"><title>5.2. Lipid Nanoparticles for Prophylactic Vaccines&#8212;A Rapid Response to COVID19:</title><p>In March 2020, the World Health Organization (WHO) declared that the Coronavirus Infectious Disease (COVID-19) was a global pandemic. In March 2021, more than 129.4 million cases and 2.8 million deaths were reported all over the world [<xref rid="B123-vaccines-09-00359" ref-type="bibr">123</xref>]. Concurrently, COVID-19 has a high probability of becoming a seasonal disease with high infection rates and a long incubation period [<xref rid="B123-vaccines-09-00359" ref-type="bibr">123</xref>]. Consequently, developing COVID-19 vaccines has been a necessity for the global population [<xref rid="B136-vaccines-09-00359" ref-type="bibr">136</xref>], for which numerous platforms have been investigated. There are 12 vaccines approved by the FDA. Others are in clinical trials, 93 vaccines are listed with 257 trials [<xref rid="B127-vaccines-09-00359" ref-type="bibr">127</xref>,<xref rid="B137-vaccines-09-00359" ref-type="bibr">137</xref>], of which, 29 vaccines in Phase 1, 39 vaccines in Phase 2, and 25 vaccines in Phase 3 [<xref rid="B137-vaccines-09-00359" ref-type="bibr">137</xref>]. The activating mechanisms in most of those vaccine candidates are based on the induction of neutralizing antibodies against the spike (S) protein to prevent the uptake into human cells via the human angiotensin-converting enzyme-2 (ACE2) receptor [<xref rid="B127-vaccines-09-00359" ref-type="bibr">127</xref>]. Thus far, for mRNA-LNPs only mRNA-1273 and BNT162 have been successfully developed and others are progressing in clinical trials (<xref rid="vaccines-09-00359-t006" ref-type="table">Table 6</xref>) [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B128-vaccines-09-00359" ref-type="bibr">128</xref>,<xref rid="B138-vaccines-09-00359" ref-type="bibr">138</xref>,<xref rid="B139-vaccines-09-00359" ref-type="bibr">139</xref>,<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>].</p><p>LNPs encapsulating mRNA developed by BioNTech SE and Pfizer for the SARS-CoV-2 vaccine had four candidates (BNT162a1, BNT162b1, BNT162b2, and BNT162c2). They were designed from two types of a nucleoside-modified mRNA, a uridine containing mRNA and a self-amplifying RNA [<xref rid="B138-vaccines-09-00359" ref-type="bibr">138</xref>,<xref rid="B141-vaccines-09-00359" ref-type="bibr">141</xref>]. They have been tested in Phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link>)in healthy volunteers aged from 18 years to 85 years [<xref rid="B142-vaccines-09-00359" ref-type="bibr">142</xref>], and in Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>) [<xref rid="B143-vaccines-09-00359" ref-type="bibr">143</xref>]. The BNT162b2 candidate has finished phase 3 clinical trials with promising results of a safe and effective vaccine. In front of the urgent need of Covid-19 vaccine, Pfizer and BioNTech submitted their BNT162b2 to the FDA to request an emergency use authorization. On 11 December 2020, the FDA approved Pfizer-BioNTech COVID-19 Vaccine distributed in the United States [<xref rid="B144-vaccines-09-00359" ref-type="bibr">144</xref>].</p><p>Using a similar strategy, mRNA-1273 COVID-19 is fabricated from synthetic mRNA inside LNPs [<xref rid="B128-vaccines-09-00359" ref-type="bibr">128</xref>,<xref rid="B145-vaccines-09-00359" ref-type="bibr">145</xref>]. This synthetic mRNA encodes for the spike, S protein of SARS-CoV-2 viruses [<xref rid="B12-vaccines-09-00359" ref-type="bibr">12</xref>,<xref rid="B138-vaccines-09-00359" ref-type="bibr">138</xref>,<xref rid="B139-vaccines-09-00359" ref-type="bibr">139</xref>] which is a key factor on viral surfaces binding to the host cell through ACE2 receptor. The S protein of SARS-CoV-2 viruses mediates cell attachment, receptor recognition, and fusion for viral penetration and infection [<xref rid="B146-vaccines-09-00359" ref-type="bibr">146</xref>]. This formula has been developed by Moderna TX, Inc, and in the process of FDA approval (phase 1) with reference number of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link> [<xref rid="B127-vaccines-09-00359" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-09-00359" ref-type="bibr">128</xref>,<xref rid="B147-vaccines-09-00359" ref-type="bibr">147</xref>]. It also moved to phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link>) to be assessed for reactogenicity, immunogenicity and safety in healthy male and non-pregnant females from 18 years old [<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B148-vaccines-09-00359" ref-type="bibr">148</xref>]. This candidate has entered Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>) to be evaluated for safety, efficacy and immunogenicity to prevent COVID-19 for up to two years [<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B149-vaccines-09-00359" ref-type="bibr">149</xref>]. On 17 December 2020, Moderna TX, Inc gained the emergency-use authorization of the FDA for mRNA-1273 [<xref rid="B150-vaccines-09-00359" ref-type="bibr">150</xref>].</p><p>McKay et al. studied LNPs encapsulated with self-amplifying RNA (saRNA) as the new SARS-CoV-2 vaccine named LNP-nCoVsaRNA or COVAC1 [<xref rid="B136-vaccines-09-00359" ref-type="bibr">136</xref>,<xref rid="B151-vaccines-09-00359" ref-type="bibr">151</xref>]. These self-amplifying RNA constructs have been proposed because any antigen of interest can be encoded and formulated at a lower dose than conventional mRNA. For in vitro and in vivo experiments, the LNP-nCoVsaRNA vaccine for SARS-CoV2 exhibited robust antibody and cellular responses. These outstanding results induced the strong belief that the LNP-nCoVsaRNA vaccine would promote immunogenicity in humans. Currently, Imperial College London applied the LNP-nCoVsaRNA vaccine for the clinical trial, currently in Phase 1 (ISRCTN17072692) [<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B152-vaccines-09-00359" ref-type="bibr">152</xref>].</p><p>Duke-NUS Medical School and Arcturus Therapeutics Inc. have collaborated for the development of a COVID-19 vaccine named ARCT-021. They used the LUNAR lipid-mediated delivery system to encapsulate RNA (STARR<sup>TM</sup>). In the preclinical stage, ARCT-021 has demonstrated to be a safe and efficient vaccine for COVID-19 at low dose. It was able to induce CD8+ T-cell and T-helper cellular immune responses without adjuvants and viral vector. Moving to Phase 1/2 clinical studies (NCT4480957), ARCT-021 has been evaluated with safety, tolerability and immunogenicity at multiple dose levels from 1&#8211;10 &#956;g. The age groups for this study are healthy people from 18&#8211;80 years, with the exception of pregnant and breast-feeding women. Preliminary data for ARCT-021 showed a favourable safety profile at a relatively low dose [<xref rid="B153-vaccines-09-00359" ref-type="bibr">153</xref>]. In addition, other similar vaccine platforms including ChulaCov19 mRNA vaccine (Chulalongkorn University) and SARS-CoV-2 mRNA vaccine (Shulan, HangzhouHospital) have applied for clinical trials. The ChulaCov19 mRNA vaccine has been registered for phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566276">NCT04566276</ext-link>) with no study recruitment yet [<xref rid="B151-vaccines-09-00359" ref-type="bibr">151</xref>]. The SARS-CoV-2 mRNA vaccine was applied to Chinese Clinical Trial Registry for Phase 1 clinical trial (ChiCTR2000034112). This trial will evaluate the safety, tolerance and immunogenicity of multiple doses in the population above 18 year olds [<xref rid="B151-vaccines-09-00359" ref-type="bibr">151</xref>].</p><p>The LNPs under development for the COVID-19 vaccines do not only include the aforementioned approved products or those still in the clinical trials, but also include numerous others that are continuously being developed in pre-clinical stage (<xref rid="vaccines-09-00359-t006" ref-type="table">Table 6</xref>) [<xref rid="B154-vaccines-09-00359" ref-type="bibr">154</xref>]. Many companies, research institutes, and universities worldwide have been listed on the WHO list with RNA-encapsulated LNP vaccines. Globe Biotech Ltd. had SARS-CoV-2 D614G variant LNP-encapsulated mRNA. Max-Planck-Institute of Colloids and Interfaces had LNPs encapsulating mRNA targeting Langerhans cell. Sanofi Pasteur and Translate Bio studied the mRNA-based vaccine MRT5500 and are going to apply for clinical trial at the ending of 2020 [<xref rid="B155-vaccines-09-00359" ref-type="bibr">155</xref>]. Now, MRT5500 has started phase1/2 clinical trial. It was expected to get interim results in the third quarter of 2021 [<xref rid="B156-vaccines-09-00359" ref-type="bibr">156</xref>]. CanSino Biologics and Precision NanoSystems had a collaboration to develop a COVID-19 RNA vaccine composed of mRNA and lipid nanoparticle carrier [<xref rid="B157-vaccines-09-00359" ref-type="bibr">157</xref>]. Daiichi-Sankyo Co. has developed mRNA-based COVID-19 vaccine named as DS-5670. For next clinical studies, Daiichi-Sankyo Co. is going to collaborate with the University of Tokyo [<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]. IMV Inc (Dartmouth, Canada), formulated their DPX-COVID-19 vaccine candidate. DPX is the lipid-based delivery system in which peptide antigens are dissolved in lipids with the final formulation stored in dry form [<xref rid="B158-vaccines-09-00359" ref-type="bibr">158</xref>]. After dissolution, this vaccine is injected intramuscularly. There is no releasing mechanism at the injection site, but the peptide antigens act as adjuvant and the formulated DPX can then recruit the antigen presenting cells that induce an immune response from the lymph nodes [<xref rid="B158-vaccines-09-00359" ref-type="bibr">158</xref>]. Na-Na Zhang et al. studied a thermostable mRNA vaccine candidate for preventing COVID-19 infection [<xref rid="B159-vaccines-09-00359" ref-type="bibr">159</xref>]. They used LNPs to encapsulate mRNA targeting the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the mouse model they used, the this LNP induced neutralizing antibodies and T-cell responses with high protective immunity against SARS-CoV-2. Additionally, this vaccine candidate can be stored at room temperature for at least one week. With these advantages, this LNP-mRNA candidate (RQ3011-RBD) is moving into phase 1 clinical trial evaluation by Fudan University, Shanghai JiaoTong University and RNACure Biopharma [<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B159-vaccines-09-00359" ref-type="bibr">159</xref>]. Moreover, they designed two other vaccine candidates, RQ3013-VLP and RQ3012-Spike, that include a cocktail of mRNA constructs. The RQ3013-VLP candidate contains a cocktail of mRNAs encoding 3 viral structural proteins of S (spike), M (membrane), and E (envelope). The RQ3012-Spike vaccine carries mRNA encoding the full-length wild-type S. In mice model, RQ3013-VLP exhibited the best immune response, across three these candidates, while RQ3011-RBD induced insufficient immunity at a low concentration of 2 &#956;g RNA/dose. Depending on these preliminary tests, it can be concluded that mRNA vaccines can act as a flexible platform to design effective candidates [<xref rid="B159-vaccines-09-00359" ref-type="bibr">159</xref>].</p><p>Besides, the developing strategy of vaccines has still studied for other diseases. Shirai et al. demonstrated that LNPs could act as an adjuvant for influenza vaccines [<xref rid="B162-vaccines-09-00359" ref-type="bibr">162</xref>]. This was confirmed through the results about the immune-stimulatory effects on dendritic cells in mice and the protection ability of LNPs encapsulating the conventional seasonal split vaccine (SV) in comparison with bare SVs and SVs combined Alum. The LNP was made of 1,2-dioleoyl-3-trimethylammonium- propane, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, N-(carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine and cholesterol. It was found that the LNPs with SVs achieved a similar efficiency as SVs combined Alum. Alum induced a high inflammatory response, which is considered a limitation of traditional adjuvants. In contrary, LNPs were able to induce SV-specific immune responses without inflammation [<xref rid="B162-vaccines-09-00359" ref-type="bibr">162</xref>]. Swaminathan et al. also assessed the adjuvant activity of LNPs alone and of LNPs incorporating the synthetic TLR9 agonist, IMO-2125 adjuvant, in a mouse model [<xref rid="B163-vaccines-09-00359" ref-type="bibr">163</xref>]. This LNP formulation was composed of DSPC, cholesterol, DMG-PEG2000 and an asymmetric ionizable amino lipid. Surprisingly, the LNP without adjuvant was able to induce B-cell responses against HbsAg (hepatitis B virus surface antigen) and ovalbumin sub-unit antigens at a comparable level than in the presence of other adjuvants including IMO-2125, 3-O-deactytaled monophosphoryl lipid and aluminum-based adjuvants. The LNP not only induced a significant enhancement of immune responses but also elicited a higher Th1-type response compared to IMO-2125 alone. So the combination of LNPs and immune-modulatory oligonucleotide adjuvants led to have the synergistic effects for immune responses and to manipulate those immune qualities that is quite different from the inorganic adjuvants.</p></sec></sec><sec sec-type="conclusions" id="sec6-vaccines-09-00359"><title>6. Conclusions and Future Directions</title><p>The clinical development of lipid-based nanoparticle technologies with chemo- and nucleic acid therapeutics have demonstrated the potential of lipid-based carriers in the treatment of a range of diseases. However, the number of successful products that have reached the market does not accurately represent the number of formulations in (pre)clinical trials, indicating that the development of these nanoparticles still suffers from difficulties and challenges in the translation from animals to humans. Recently, several strategies have been developed to overcome these limitations. To improve the stability of nanoparticles and prevent drug leakage, lipid structures have been designed that efficiently complex by ionic attraction with the encapsulated therapeutic. Ionizable lipids, such as DOP-DEDA, have shown to be favourable for gene encapsulation. Cholesterol, on the other hand, is essential in providing stability to the liposomal structures resulting in tight packing of the drugs. Stability of the LNPs in physiological media and systemic circulation is achieved by modifying the particle surface with a PEG-lipid, thereby reducing the recognization by the reticuloendothelial system. However, the production of anti-PEG antibodies following administration of the first dose has been reported to reduce the therapeutic efficacy and/or cause adverse reactions upon the following doses. The quest for PEG alternatives has, therefore, become necessary to enable repeated injections. Besides the prolonged circulation, LNPs must target the specific tissues/cells/organs and then internalize through cell membranes to release drugs at the site of action. To achieve this requirement, LNPs have been designed as smart materials with selective ligands with degradation being triggered by changes in pH, temperature or oxidation/reduction. </p><p>The selective association of LNPs with target cells remains a challenge. Nucleic acid vaccines for example cannot be injected directly into our lymph nodes or spleen, which are tissues that are home to immune cells responsible for making antibodies and killing cancer cells. The targeted delivery of nucleic acids from injection sites to immune cells in lymph nodes or the spleen is therefore critical to maximising the production of antibody or long-lived antigen-specific cytotoxic T cells. Such delivery systems need the ability to target lymph nodes but also cross the barrier cells in the lymph nodes to interact with immune cells. Additionally, after internalization, the controlled release of therapeutics to aberrant cells has to be initiated effectively. These mechanisms that facilitate cell uptake, internalization, and payload release have not yet achieved the expected results. The success of LNPs with selective ligands in the market have not been completed yet. Therefore, with various cell type-specific ligands and stimulus agents, it is expected that studies related efficacy of modified LNPs for different diseases will enter clinical trials soon. The co-delivery or drug co-encapsulating with adjuvants are of interest in this field to improve efficacy and immune modulation. Additionally, the manufacturing and scaling up process of LNPs, has been challenging. New methodologies of LNP preparation based on microfluidics have been considered as the most robust to date, but it exhibits limitations in formulating multifunctional LNPs. </p><p>Concurrently, to combat the COVID-19 pandemic, the fast development of RNA and LNP-based vaccines have gained emergency FDA approval, which demonstrates the rapid and effective response of this approach against complex diseases. These vaccines are not limited to infectious diseases but have also been developed for other disease types such as cancer and hyperlipidemia. Some clinical trials are almost at the final phase. Numerous studies are at early stages and will increase in the future, which forecasts a range of products to be launched on the market.</p><p>In conclusion, we believe that the success of mRNA-LNP vaccines opens an exciting chapter for LNP technology. A long road to optimizing LNP formulations for small molecule drugs and nucleic acid delivery has been paid off, and LNPs have become, once again, a frontrunner in nano drug delivery system. This review highlights key lessons learnt from this long road and serves as a reference for designing LNPs. Further development of LNPs is still urgently needed to address current global health challenges, which requires collaborative efforts of scientists in different fields.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, N.P.T.; writing&#8212;original draft preparation, T.T.H.T. and E.J.A.S.; writing&#8212;editing, E.J.A.S. and N.P.T.; writing&#8212;review, J.S.L., D.H.N., and K.D.P.; funding acquisition, N.P.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by the Australian Research Council and the National Health and Medical Research Council, grant number DE180100076, DP200100231 and GNT2002827.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-09-00359"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ventola</surname><given-names>C.L.</given-names></name></person-group><article-title>Progress in nanomedicine: Approved and investigational nanodrugs</article-title><source>PT Peer-Rev. J. Formul. Manag.</source><year>2017</year><volume>42</volume><fpage>742</fpage><lpage>755</lpage><pub-id pub-id-type="pmcid">PMC5720487</pub-id><pub-id pub-id-type="pmid">29234213</pub-id></element-citation></ref><ref id="B2-vaccines-09-00359"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bobo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thurecht</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Corrie</surname><given-names>S.R.</given-names></name></person-group><article-title>Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date</article-title><source>Pharm. Res.</source><year>2016</year><volume>33</volume><fpage>2373</fpage><elocation-id>2387</elocation-id><pub-id pub-id-type="doi">10.1007/s11095-016-1958-5</pub-id><pub-id pub-id-type="pmid">27299311</pub-id></element-citation></ref><ref id="B3-vaccines-09-00359"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anselmo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Nanoparticles in the clinic: An update</article-title><source>Bioeng. Transl. Med.</source><year>2019</year><volume>4</volume><elocation-id>e10143</elocation-id><pub-id pub-id-type="doi">10.1002/btm2.10143</pub-id><pub-id pub-id-type="pmid">31572799</pub-id><pub-id pub-id-type="pmcid">PMC6764803</pub-id></element-citation></ref><ref id="B4-vaccines-09-00359"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tosi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Spring</surname><given-names>K.</given-names></name><name name-style="western"><surname>&#197;slund</surname><given-names>A.K.O.</given-names></name><name name-style="western"><surname>Pottier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schiffelers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ceccaldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>R.</given-names></name></person-group><article-title>Delivering the power of nanomedicine to patients today</article-title><source>J. Control. Release</source><year>2020</year><volume>326</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.007</pub-id><pub-id pub-id-type="pmid">32681950</pub-id><pub-id pub-id-type="pmcid">PMC7362824</pub-id></element-citation></ref><ref id="B5-vaccines-09-00359"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabnis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumarasinghe</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mihai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ketova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Senn</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bulychev</surname><given-names>A.</given-names></name><name name-style="western"><surname>McFadyen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates</article-title><source>Mol. Ther.</source><year>2018</year><volume>26</volume><fpage>1509</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.03.010</pub-id><pub-id pub-id-type="pmid">29653760</pub-id><pub-id pub-id-type="pmcid">PMC5986714</pub-id></element-citation></ref><ref id="B6-vaccines-09-00359"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nagarsenker</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name></person-group><article-title>Liposomes: Advancements and innovation in the manufacturing process</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#8211;155</volume><fpage>102</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.002</pub-id><pub-id pub-id-type="pmid">32650041</pub-id></element-citation></ref><ref id="B7-vaccines-09-00359"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name></person-group><article-title>Nanomedicines: Redefining traditional medicine</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>134</volume><elocation-id>111103</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2020.111103</pub-id><pub-id pub-id-type="pmid">33338747</pub-id></element-citation></ref><ref id="B8-vaccines-09-00359"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soininen</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Repo</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Karttunen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Auriola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vahakangas</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Ruponen</surname><given-names>M.</given-names></name></person-group><article-title>Human placental cell and tissue uptake of doxorubicin and its liposomal formulations</article-title><source>Toxicol. Lett.</source><year>2015</year><volume>239</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2015.09.011</pub-id><pub-id pub-id-type="pmid">26383631</pub-id></element-citation></ref><ref id="B9-vaccines-09-00359"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barenholz</surname><given-names>Y.</given-names></name></person-group><article-title>Doxil(R)-the first FDA-approved nano-drug: Lessons learned</article-title><source>J. Control. Release</source><year>2012</year><volume>160</volume><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.03.020</pub-id><pub-id pub-id-type="pmid">22484195</pub-id></element-citation></ref><ref id="B10-vaccines-09-00359"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khvorova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>J.K.</given-names></name></person-group><article-title>The chemical evolution of oligonucleotide therapies of clinical utility</article-title><source>Nat. Biotechnol.</source><year>2017</year><volume>35</volume><fpage>238</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nbt.3765</pub-id><pub-id pub-id-type="pmid">28244990</pub-id><pub-id pub-id-type="pmcid">PMC5517098</pub-id></element-citation></ref><ref id="B11-vaccines-09-00359"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichmuth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Oberli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccine delivery using lipid nanoparticles</article-title><source>Ther. Deliv.</source><year>2016</year><volume>7</volume><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.4155/tde-2016-0006</pub-id><pub-id pub-id-type="pmid">27075952</pub-id><pub-id pub-id-type="pmcid">PMC5439223</pub-id></element-citation></ref><ref id="B12-vaccines-09-00359"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaridou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heyes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lutwyche</surname><given-names>P.</given-names></name></person-group><article-title>Lipid nanoparticles for nucleic acid delivery: Current perspectives</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#8211;155</volume><fpage>37</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.002</pub-id><pub-id pub-id-type="pmid">32526452</pub-id></element-citation></ref><ref id="B13-vaccines-09-00359"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>167</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.003</pub-id><pub-id pub-id-type="pmid">32512027</pub-id></element-citation></ref><ref id="B14-vaccines-09-00359"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ickenstein</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Garidel</surname><given-names>P.</given-names></name></person-group><article-title>Lipid-based nanoparticle formulations for small molecules and RNA drugs</article-title><source>Expert Opin. Drug Deliv.</source><year>2019</year><volume>16</volume><fpage>1205</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1080/17425247.2019.1669558</pub-id><pub-id pub-id-type="pmid">31530041</pub-id></element-citation></ref><ref id="B15-vaccines-09-00359"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Witzigmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.Y.C.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name></person-group><article-title>On the role of helper lipids in lipid nanoparticle formulations of siRNA</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><fpage>21733</fpage><lpage>21739</lpage><pub-id pub-id-type="doi">10.1039/C9NR09347H</pub-id><pub-id pub-id-type="pmid">31713568</pub-id></element-citation></ref><ref id="B16-vaccines-09-00359"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akinc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jayaraman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ansell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>T.D.</given-names></name><etal/></person-group><article-title>The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs</article-title><source>Nat. Nanotechnol.</source><year>2019</year><volume>14</volume><fpage>1084</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1038/s41565-019-0591-y</pub-id><pub-id pub-id-type="pmid">31802031</pub-id></element-citation></ref><ref id="B17-vaccines-09-00359"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;ttger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pauli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>P.-H.</given-names></name><name name-style="western"><surname>Al Fayez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hohenwarter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-D.</given-names></name></person-group><article-title>Lipid-based nanoparticle technologies for liver targeting</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#8211;155</volume><fpage>79</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.017</pub-id><pub-id pub-id-type="pmid">32574575</pub-id></element-citation></ref><ref id="B18-vaccines-09-00359"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semple</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Akinc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Mui</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>D.W.Y.</given-names></name><name name-style="western"><surname>Stebbing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crosley</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Yaworski</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Rational design of cationic lipids for siRNA delivery</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nbt.1602</pub-id><pub-id pub-id-type="pmid">20081866</pub-id></element-citation></ref><ref id="B19-vaccines-09-00359"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassett</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Benenato</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Jacquinet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deterling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geilich</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Ketova</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Optimization of lipid nanoparticles for intramuscular administration of mRNA Vaccines</article-title><source>Mol. Ther. Nucleic Acids</source><year>2019</year><volume>15</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2019.01.013</pub-id><pub-id pub-id-type="pmid">30785039</pub-id><pub-id pub-id-type="pmcid">PMC6383180</pub-id></element-citation></ref><ref id="B20-vaccines-09-00359"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramezanpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bodnariuc</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S.S.W.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Thewalt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tieleman</surname><given-names>D.P.</given-names></name></person-group><article-title>Ionizable amino lipid interactions with POPC: Implications for lipid nanoparticle function</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><fpage>14141</fpage><lpage>14146</lpage><pub-id pub-id-type="doi">10.1039/C9NR02297J</pub-id><pub-id pub-id-type="pmid">31334542</pub-id></element-citation></ref><ref id="B21-vaccines-09-00359"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayaraman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ansell</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mui</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eltepu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narayanannair</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo</article-title><source>Angew. Chem. Int. Ed.</source><year>2012</year><volume>51</volume><fpage>8529</fpage><lpage>8533</lpage><pub-id pub-id-type="doi">10.1002/anie.201203263</pub-id><pub-id pub-id-type="pmcid">PMC3470698</pub-id><pub-id pub-id-type="pmid">22782619</pub-id></element-citation></ref><ref id="B22-vaccines-09-00359"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Darjuan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thewalt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.Y.C.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name></person-group><article-title>On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>4787</fpage><lpage>4795</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b01516</pub-id><pub-id pub-id-type="pmid">29614232</pub-id></element-citation></ref><ref id="B23-vaccines-09-00359"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ely</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Arbuthnot</surname><given-names>P.</given-names></name></person-group><article-title>In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.addr.2020.05.010</pub-id><pub-id pub-id-type="pmid">32485207</pub-id></element-citation></ref><ref id="B24-vaccines-09-00359"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mashel</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Tarakanchikova</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Muslimov</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Zyuzin</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Timin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Lepik</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Fehse</surname><given-names>B.</given-names></name></person-group><article-title>Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods</article-title><source>Biomaterials</source><year>2020</year><volume>258</volume><elocation-id>120282</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120282</pub-id><pub-id pub-id-type="pmid">32798742</pub-id></element-citation></ref><ref id="B25-vaccines-09-00359"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapeinos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Battaglini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciofani</surname><given-names>G.</given-names></name></person-group><article-title>Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases</article-title><source>J. Control. Release</source><year>2017</year><volume>264</volume><fpage>306</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.08.033</pub-id><pub-id pub-id-type="pmid">28844756</pub-id><pub-id pub-id-type="pmcid">PMC6701993</pub-id></element-citation></ref><ref id="B26-vaccines-09-00359"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yonezawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koide</surname><given-names>H.</given-names></name><name name-style="western"><surname>Asai</surname><given-names>T.</given-names></name></person-group><article-title>Recent advances in siRNA delivery mediated by lipid-based nanoparticles</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#8211;155</volume><fpage>64</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.022</pub-id><pub-id pub-id-type="pmcid">PMC7406478</pub-id><pub-id pub-id-type="pmid">32768564</pub-id></element-citation></ref><ref id="B27-vaccines-09-00359"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chacko</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Ghate</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Dsouza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.A.</given-names></name></person-group><article-title>Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications</article-title><source>Colloids Surf. B Biointerfaces</source><year>2020</year><volume>195</volume><elocation-id>111262</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111262</pub-id><pub-id pub-id-type="pmid">32736123</pub-id></element-citation></ref><ref id="B28-vaccines-09-00359"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opatha</surname><given-names>S.A.T.</given-names></name><name name-style="western"><surname>Titapiwatanakun</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chutoprapat</surname><given-names>R.</given-names></name></person-group><article-title>Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>855</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12090855</pub-id><pub-id pub-id-type="pmid">32916782</pub-id><pub-id pub-id-type="pmcid">PMC7559928</pub-id></element-citation></ref><ref id="B29-vaccines-09-00359"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khimani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neogi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Siva Kumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vekariya</surname><given-names>R.L.</given-names></name></person-group><article-title>A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>26777</fpage><lpage>26791</lpage><pub-id pub-id-type="doi">10.1039/D0RA03491F</pub-id><pub-id pub-id-type="pmcid">PMC9055574</pub-id><pub-id pub-id-type="pmid">35515778</pub-id></element-citation></ref><ref id="B30-vaccines-09-00359"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name></person-group><article-title>Niosomes: A review on niosomal research in the last decade</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>56</volume><elocation-id>101581</elocation-id><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101581</pub-id></element-citation></ref><ref id="B31-vaccines-09-00359"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P.K.</given-names></name></person-group><article-title>Invasomes: Potential vesicular systems for transdermal delivery of drug molecules</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><elocation-id>102166</elocation-id><pub-id pub-id-type="doi">10.1016/j.jddst.2020.102166</pub-id></element-citation></ref><ref id="B32-vaccines-09-00359"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasirizadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malaekeh-Nikouei</surname><given-names>B.</given-names></name></person-group><article-title>Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>55</volume><elocation-id>101458</elocation-id><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101458</pub-id></element-citation></ref><ref id="B33-vaccines-09-00359"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Michalowski</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Beloqui</surname><given-names>A.</given-names></name></person-group><article-title>Advances in lipid carriers for drug delivery to the gastrointestinal tract</article-title><source>Curr. Opin. Colloid Interface Sci.</source><year>2020</year><elocation-id>101414</elocation-id><pub-id pub-id-type="doi">10.1016/j.cocis.2020.101414</pub-id></element-citation></ref><ref id="B34-vaccines-09-00359"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abouelfetouh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name></person-group><article-title>Solid lipid nanoparticles for enhanced oral absorption: A review</article-title><source>Colloids Surf. B Biointerfaces</source><year>2020</year><volume>196</volume><elocation-id>111305</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111305</pub-id><pub-id pub-id-type="pmid">32795844</pub-id></element-citation></ref><ref id="B35-vaccines-09-00359"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freitas</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>R.H.</given-names></name></person-group><article-title>Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase</article-title><source>Eur. J. Pharm. Biopharm.</source><year>1999</year><volume>47</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/S0939-6411(98)00074-5</pub-id><pub-id pub-id-type="pmid">10234536</pub-id></element-citation></ref><ref id="B36-vaccines-09-00359"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laffleur</surname><given-names>F.</given-names></name><name name-style="western"><surname>Keckeis</surname><given-names>V.</given-names></name></person-group><article-title>Advances in drug delivery systems: Work in progress still needed?</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>590</volume><elocation-id>119912</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119912</pub-id><pub-id pub-id-type="pmid">32971178</pub-id></element-citation></ref><ref id="B37-vaccines-09-00359"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T.</given-names></name></person-group><article-title>Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery</article-title><source>Biomed. Pharm.</source><year>2019</year><volume>109</volume><fpage>475</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.158</pub-id><pub-id pub-id-type="pmid">30399584</pub-id></element-citation></ref><ref id="B38-vaccines-09-00359"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basha</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Dhandayuthabani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muzammil</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>V.S.</given-names></name></person-group><article-title>Solid lipid nanoparticles for oral drug delivery</article-title><source>Mater. Today Proc.</source><year>2020</year><volume>36</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.matpr.2020.04.109</pub-id></element-citation></ref><ref id="B39-vaccines-09-00359"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veiga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diesendruck</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D.</given-names></name></person-group><article-title>Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>159</volume><fpage>364</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.04.002</pub-id><pub-id pub-id-type="pmid">32298783</pub-id></element-citation></ref><ref id="B40-vaccines-09-00359"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maeki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tokeshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution</article-title><source>Mol. Pharm.</source><year>2020</year><volume>17</volume><fpage>944</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01182</pub-id><pub-id pub-id-type="pmid">31990567</pub-id></element-citation></ref><ref id="B41-vaccines-09-00359"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oussoren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zuidema</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crommelin</surname><given-names>D.J.A.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name></person-group><article-title>Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: II. Influence of liposomal size, lipid composition and lipid dose</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>1997</year><volume>1328</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/S0005-2736(97)00122-3</pub-id><pub-id pub-id-type="pmid">9315622</pub-id></element-citation></ref><ref id="B42-vaccines-09-00359"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisse</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Zanger</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Charels</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Smissen</surname><given-names>P.</given-names></name><name name-style="western"><surname>McCuskey</surname><given-names>R.S.</given-names></name></person-group><article-title>The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse</article-title><source>Hepatology</source><year>1985</year><volume>5</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1002/hep.1840050427</pub-id><pub-id pub-id-type="pmid">3926620</pub-id></element-citation></ref><ref id="B43-vaccines-09-00359"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Elewa</surname><given-names>Y.H.A.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo</article-title><source>J. Control Release</source><year>2021</year><volume>331</volume><fpage>335</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.01.021</pub-id><pub-id pub-id-type="pmid">33484779</pub-id></element-citation></ref><ref id="B44-vaccines-09-00359"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thauvin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mottas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Delie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Allemann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bourquin</surname><given-names>C.</given-names></name></person-group><article-title>Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>535</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.11.031</pub-id><pub-id pub-id-type="pmid">29157965</pub-id></element-citation></ref><ref id="B45-vaccines-09-00359"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilkington</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Veldhuis</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N.P.</given-names></name></person-group><article-title>Cellular interactions of liposomes and PISA nanoparticles during human blood flow in a microvascular network</article-title><source>Small</source><year>2020</year><volume>16</volume><elocation-id>e2002861</elocation-id><pub-id pub-id-type="doi">10.1002/smll.202002861</pub-id><pub-id pub-id-type="pmid">32583981</pub-id><pub-id pub-id-type="pmcid">PMC7361276</pub-id></element-citation></ref><ref id="B46-vaccines-09-00359"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksen-Lacey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bramwell</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Lindenstr&#248;m</surname><given-names>T.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name></person-group><article-title>Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3&#946;-[N-(N&#8242;,N&#8242;-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged liposome retention mediates stronger Th1 responses</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1021/mp100208f</pub-id><pub-id pub-id-type="pmid">21117621</pub-id></element-citation></ref><ref id="B47-vaccines-09-00359"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hatakeyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo</article-title><source>J. Control Release</source><year>2012</year><volume>163</volume><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.09.009</pub-id><pub-id pub-id-type="pmid">23000694</pub-id></element-citation></ref><ref id="B48-vaccines-09-00359"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saeki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koide</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fukata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oku</surname><given-names>N.</given-names></name><name name-style="western"><surname>Asai</surname><given-names>T.</given-names></name></person-group><article-title>Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>585</volume><elocation-id>119479</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119479</pub-id><pub-id pub-id-type="pmid">32473372</pub-id></element-citation></ref><ref id="B49-vaccines-09-00359"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anderluzzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gallorini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brazzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferlenghi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.W.</given-names></name><etal/></person-group><article-title>Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection</article-title><source>J. Control. Release</source><year>2020</year><volume>325</volume><fpage>370</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.06.027</pub-id><pub-id pub-id-type="pmid">32619745</pub-id></element-citation></ref><ref id="B50-vaccines-09-00359"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Siegwart</surname><given-names>D.J.</given-names></name></person-group><article-title>Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><elocation-id>3232</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17029-3</pub-id><pub-id pub-id-type="pmid">32591530</pub-id><pub-id pub-id-type="pmcid">PMC7320157</pub-id></element-citation></ref><ref id="B51-vaccines-09-00359"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghimi</surname><given-names>S.M.</given-names></name></person-group><article-title>The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes</article-title><source>Biomaterials</source><year>2006</year><volume>27</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2005.05.082</pub-id><pub-id pub-id-type="pmid">16019063</pub-id></element-citation></ref><ref id="B52-vaccines-09-00359"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zukancic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Suys</surname><given-names>E.J.A.</given-names></name><name name-style="western"><surname>Pilkington</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Algarni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Wassiti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N.P.</given-names></name></person-group><article-title>the importance of poly(ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12111068</pub-id><pub-id pub-id-type="pmid">33182382</pub-id><pub-id pub-id-type="pmcid">PMC7695259</pub-id></element-citation></ref><ref id="B53-vaccines-09-00359"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoang Thi</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Pilkington</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N.P.</given-names></name></person-group><article-title>The importance of poly(ethylene glycol) alternatives for overcoming peg immunogenicity in drug delivery and bioconjugation</article-title><source>Polymers</source><year>2020</year><volume>12</volume><elocation-id>298</elocation-id><pub-id pub-id-type="doi">10.3390/polym12020298</pub-id><pub-id pub-id-type="pmid">32024289</pub-id><pub-id pub-id-type="pmcid">PMC7077443</pub-id></element-citation></ref><ref id="B54-vaccines-09-00359"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.-X.</given-names></name><name name-style="western"><surname>Juno</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Esterbauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name></person-group><article-title>Hemagglutinin functionalized liposomal vaccines enhance germinal center and follicular helper T cell immunity</article-title><source>Adv. Healthc. Mater.</source><year>2002</year><volume>142</volume><elocation-id>2002142</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202002142</pub-id><pub-id pub-id-type="pmcid">PMC8206650</pub-id><pub-id pub-id-type="pmid">33690985</pub-id></element-citation></ref><ref id="B55-vaccines-09-00359"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veiga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diesendruck</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ramishetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E.</given-names></name><name name-style="western"><surname>Behlke</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Benhar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D.</given-names></name></person-group><article-title>Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target</article-title><source>J. Control. Release</source><year>2019</year><volume>313</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.10.001</pub-id><pub-id pub-id-type="pmid">31634546</pub-id></element-citation></ref><ref id="B56-vaccines-09-00359"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedmi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veiga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramishetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dammes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hazan-Halevy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nahary</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leviatan-Ben-Arye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harlev</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A modular platform for targeted RNAi therapeutics</article-title><source>Nat. Nanotechnol.</source><year>2018</year><volume>13</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/s41565-017-0043-5</pub-id><pub-id pub-id-type="pmid">29379205</pub-id></element-citation></ref><ref id="B57-vaccines-09-00359"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veiga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Granot</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dammes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kedmi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramishetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D.</given-names></name></person-group><article-title>Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><elocation-id>4493</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06936-1</pub-id><pub-id pub-id-type="pmid">30374059</pub-id><pub-id pub-id-type="pmcid">PMC6206083</pub-id></element-citation></ref><ref id="B58-vaccines-09-00359"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#228;&#228;lik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lingasamy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Toome</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mastandrea</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rousso-Noori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tobi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sim&#243;n-Gracia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Paiste</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kotamraju</surname><given-names>V.R.</given-names></name><etal/></person-group><article-title>Peptide-guided nanoparticles for glioblastoma targeting</article-title><source>J. Control. Release</source><year>2019</year><volume>308</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.06.018</pub-id><pub-id pub-id-type="pmid">31255690</pub-id></element-citation></ref><ref id="B59-vaccines-09-00359"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sim&#243;n-Gracia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tobi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kotamraju</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nigul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sugahara</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Ruoslahti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Teesalu</surname><given-names>T.</given-names></name></person-group><article-title>Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles</article-title><source>J. Control. Release</source><year>2017</year><volume>260</volume><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.06.005</pub-id><pub-id pub-id-type="pmid">28603028</pub-id><pub-id pub-id-type="pmcid">PMC6129970</pub-id></element-citation></ref><ref id="B60-vaccines-09-00359"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Shih-Huang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Rajesh</surname><given-names>R.</given-names></name></person-group><article-title>Enhanced integrin affinity and neural differentiation of induced pluripotent stem cells using Ln5-P4-grafted amphiphilic solid lipid nanoparticles</article-title><source>Mater. Sci. Eng. C</source><year>2021</year><volume>118</volume><elocation-id>111339</elocation-id><pub-id pub-id-type="doi">10.1016/j.msec.2020.111339</pub-id><pub-id pub-id-type="pmid">33254967</pub-id></element-citation></ref><ref id="B61-vaccines-09-00359"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez-Erviti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seow</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Betts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lakhal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>M.J.A.</given-names></name></person-group><article-title>Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes</article-title><source>Nat. Biotechnol.</source><year>2011</year><volume>29</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nbt.1807</pub-id><pub-id pub-id-type="pmid">21423189</pub-id></element-citation></ref><ref id="B62-vaccines-09-00359"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kogure</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Serada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Futaki</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation</article-title><source>J. Control. Release</source><year>2010</year><volume>143</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.01.012</pub-id><pub-id pub-id-type="pmid">20080139</pub-id></element-citation></ref><ref id="B63-vaccines-09-00359"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Midoux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pichon</surname><given-names>C.</given-names></name></person-group><article-title>Lipid-based mRNA vaccine delivery systems</article-title><source>Expert. Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.986104</pub-id><pub-id pub-id-type="pmid">25540984</pub-id></element-citation></ref><ref id="B64-vaccines-09-00359"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Munye</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Tagalakis</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Manunta</surname><given-names>M.D.I.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>S.L.</given-names></name></person-group><article-title>The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><elocation-id>7107</elocation-id><pub-id pub-id-type="doi">10.1038/srep07107</pub-id><pub-id pub-id-type="pmid">25407686</pub-id><pub-id pub-id-type="pmcid">PMC4236742</pub-id></element-citation></ref><ref id="B65-vaccines-09-00359"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name></person-group><article-title>Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo</article-title><source>Acta Biomater.</source><year>2019</year><volume>92</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.05.034</pub-id><pub-id pub-id-type="pmid">31102765</pub-id></element-citation></ref><ref id="B66-vaccines-09-00359"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.C.</given-names></name></person-group><article-title>Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>510</volume><fpage>394</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.06.127</pub-id><pub-id pub-id-type="pmid">27374198</pub-id></element-citation></ref><ref id="B67-vaccines-09-00359"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name></person-group><article-title>Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>138</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.11.041</pub-id><pub-id pub-id-type="pmid">26655793</pub-id></element-citation></ref><ref id="B68-vaccines-09-00359"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deken</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kijanka</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Beltran Hernandez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Slooter</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>van Diest</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>van Bergen En Henegouwen</surname><given-names>P.M.P.</given-names></name><name name-style="western"><surname>Lowik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Vahrmeijer</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session</article-title><source>J. Control Release</source><year>2020</year><volume>323</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.04.030</pub-id><pub-id pub-id-type="pmid">32330574</pub-id><pub-id pub-id-type="pmcid">PMC7116241</pub-id></element-citation></ref><ref id="B69-vaccines-09-00359"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.Y.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaifman</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ciufolini</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name></person-group><article-title>The niemann-pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA</article-title><source>Mol. Ther.</source><year>2016</year><volume>24</volume><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.179</pub-id><pub-id pub-id-type="pmid">27633442</pub-id><pub-id pub-id-type="pmcid">PMC5167785</pub-id></element-citation></ref><ref id="B70-vaccines-09-00359"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ajazuddin</surname></name><name name-style="western"><surname>Ravichandiran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Murty</surname><given-names>U.S.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>A.</given-names></name></person-group><article-title>Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting</article-title><source>J. Control. Release</source><year>2020</year><volume>321</volume><fpage>372</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.02.020</pub-id><pub-id pub-id-type="pmid">32061621</pub-id></element-citation></ref><ref id="B71-vaccines-09-00359"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Marioli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name></person-group><article-title>Analytical characterization of liposomes and other lipid nanoparticles for drug delivery</article-title><source>J. Pharm. Biomed. Anal.</source><year>2021</year><volume>192</volume><elocation-id>113642</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpba.2020.113642</pub-id><pub-id pub-id-type="pmid">33011580</pub-id></element-citation></ref><ref id="B72-vaccines-09-00359"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamichhane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Udayakumar</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>D&#8217;Souza</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Simone</surname><given-names>C.B.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Raghavan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Polf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>J.</given-names></name></person-group><article-title>Liposomes: Clinical applications and potential for image-guided drug delivery</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>288</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23020288</pub-id><pub-id pub-id-type="pmid">29385755</pub-id><pub-id pub-id-type="pmcid">PMC6017282</pub-id></element-citation></ref><ref id="B73-vaccines-09-00359"><label>73.</label><element-citation publication-type="web"><article-title>Mebiopharm&#8212;Product &amp; Technologies</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mebiopharm.com/english/pro.html">http://www.mebiopharm.com/english/pro.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-21">(accessed on 21 January 2021)</date-in-citation></element-citation></ref><ref id="B74-vaccines-09-00359"><label>74.</label><element-citation publication-type="web"><article-title>ThermoDox&#174;&#8212;Enhancing the Efficacy of Doxorubicin with Heat-Activated Liposome Technology</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://celsion.com/thermodox/">https://celsion.com/thermodox/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-02-10">(accessed on 10 February 2021)</date-in-citation></element-citation></ref><ref id="B75-vaccines-09-00359"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krop</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wickham</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study</article-title><source>Br. J. Cancer</source><year>2018</year><volume>119</volume><fpage>1086</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0235-2</pub-id><pub-id pub-id-type="pmid">30361524</pub-id><pub-id pub-id-type="pmcid">PMC6219487</pub-id></element-citation></ref><ref id="B76-vaccines-09-00359"><label>76.</label><element-citation publication-type="web"><article-title>Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.prnewswire.com/news-releases/merrimack-stops-the-phase-2-hermione-trial-of-mm-302-in-her2-positive-metastatic-breast-cancer-patients-300382177.html">https://www.prnewswire.com/news-releases/merrimack-stops-the-phase-2-hermione-trial-of-mm-302-in-her2-positive-metastatic-breast-cancer-patients-300382177.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B77-vaccines-09-00359"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seetharamu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hochster</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muggia</surname><given-names>F.</given-names></name></person-group><article-title>Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer</article-title><source>Anticancer Res.</source><year>2010</year><volume>30</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">20332467</pub-id></element-citation></ref><ref id="B78-vaccines-09-00359"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khuri</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Tonda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Herbst</surname><given-names>R.S.</given-names></name></person-group><article-title>A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2001</year><volume>34</volume><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(01)00278-1</pub-id><pub-id pub-id-type="pmid">11714540</pub-id></element-citation></ref><ref id="B79-vaccines-09-00359"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lorigan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Margison</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Margison</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M.</given-names></name></person-group><article-title>Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer</article-title><source>Br. J. Cancer</source><year>2006</year><volume>95</volume><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603345</pub-id><pub-id pub-id-type="pmid">16969346</pub-id><pub-id pub-id-type="pmcid">PMC2360546</pub-id></element-citation></ref><ref id="B80-vaccines-09-00359"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Strychor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Stoller</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Belani</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Maruca</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies</article-title><source>J. Clin. Pharm.</source><year>2012</year><volume>52</volume><fpage>180</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1177/0091270010394851</pub-id><pub-id pub-id-type="pmid">21233302</pub-id></element-citation></ref><ref id="B81-vaccines-09-00359"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Development of liposomal formulations: From concept to clinical investigations</article-title><source>Asian J. Pharm. Sci.</source><year>2013</year><volume>8</volume><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2013.07.010</pub-id></element-citation></ref><ref id="B82-vaccines-09-00359"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulbake</surname><given-names>U.</given-names></name><name name-style="western"><surname>Doppalapudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kommineni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name></person-group><article-title>Liposomal formulations in clinical use: An updated review</article-title><source>Pharmaceutics</source><year>2017</year><volume>9</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics9020012</pub-id><pub-id pub-id-type="pmcid">PMC5489929</pub-id><pub-id pub-id-type="pmid">28346375</pub-id></element-citation></ref><ref id="B83-vaccines-09-00359"><label>83.</label><element-citation publication-type="gov"><article-title>TLD-1, a Novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03387917">https://clinicaltrials.gov/ct2/show/NCT03387917</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-12">(accessed on 12 March 2021)</date-in-citation></element-citation></ref><ref id="B84-vaccines-09-00359"><label>84.</label><element-citation publication-type="gov"><article-title>Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00765973">https://clinicaltrials.gov/ct2/show/NCT00765973</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-21">(accessed on 21 January 2021)</date-in-citation></element-citation></ref><ref id="B85-vaccines-09-00359"><label>85.</label><element-citation publication-type="gov"><article-title>Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00964080">https://clinicaltrials.gov/ct2/show/NCT00964080</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-02-20">(accessed on 20 February 2021)</date-in-citation></element-citation></ref><ref id="B86-vaccines-09-00359"><label>86.</label><element-citation publication-type="gov"><article-title>Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00617981">https://clinicaltrials.gov/ct2/show/NCT00617981</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-02-20">(accessed on 20 February 2021)</date-in-citation></element-citation></ref><ref id="B87-vaccines-09-00359"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R.</given-names></name></person-group><article-title>Lipid nanoparticles enabling gene therapies: From concepts to clinical utility</article-title><source>Nucleic Acid Ther.</source><year>2018</year><volume>28</volume><fpage>146</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1089/nat.2018.0721</pub-id><pub-id pub-id-type="pmid">29683383</pub-id></element-citation></ref><ref id="B88-vaccines-09-00359"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shakur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhagchandani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Trends in therapeutic conjugates: Bench to clinic</article-title><source>Bioconjugate Chem.</source><year>2020</year><volume>31</volume><fpage>462</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.9b00828</pub-id><pub-id pub-id-type="pmid">31990184</pub-id></element-citation></ref><ref id="B89-vaccines-09-00359"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name></person-group><article-title>Therapeutic siRNA: State of the art</article-title><source>Signal Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><elocation-id>101</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-0207-x</pub-id><pub-id pub-id-type="pmid">32561705</pub-id><pub-id pub-id-type="pmcid">PMC7305320</pub-id></element-citation></ref><ref id="B90-vaccines-09-00359"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>L.J.</given-names></name></person-group><article-title>Givosiran&#8212;First Approval</article-title><source>Drugs</source><year>2020</year><volume>80</volume><fpage>335</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01269-0</pub-id><pub-id pub-id-type="pmid">32034693</pub-id></element-citation></ref><ref id="B91-vaccines-09-00359"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mucker</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Karmali</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Vega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwilas</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Joselyn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ballantyne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sampey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mukthavaram</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>8764</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-65059-0</pub-id><pub-id pub-id-type="pmid">32472093</pub-id><pub-id pub-id-type="pmcid">PMC7260227</pub-id></element-citation></ref><ref id="B92-vaccines-09-00359"><label>92.</label><element-citation publication-type="web"><article-title>Addressing Key Challenges of Lipid-Mediated Delivery Systems for mRNA through Innovation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://endpts.com/sp/addressing-key-challenges-of-lipid-mediated-delivery-systems-for-mrna-through-innovation/">https://endpts.com/sp/addressing-key-challenges-of-lipid-mediated-delivery-systems-for-mrna-through-innovation/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-28">(accessed on 28 January 2021)</date-in-citation></element-citation></ref><ref id="B93-vaccines-09-00359"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaswamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tonnu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tachikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Limphong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vega</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Karmali</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Chivukula</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>I.M.</given-names></name></person-group><article-title>Systemic delivery of factor IX messenger RNA for protein replacement therapy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E1941</fpage><lpage>E1950</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619653114</pub-id><pub-id pub-id-type="pmid">28202722</pub-id><pub-id pub-id-type="pmcid">PMC5347596</pub-id></element-citation></ref><ref id="B94-vaccines-09-00359"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demeure</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Armaghany</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ejadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Elfiky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strosberg</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Whitsett</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Sekar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC)</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><elocation-id>2547</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.2547</pub-id></element-citation></ref><ref id="B95-vaccines-09-00359"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halfdanarson</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Armaghany</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ejadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Northfelt</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Strosberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Vaena</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fredlund</surname><given-names>P.</given-names></name><name name-style="western"><surname>Semple</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>A phase I/II study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1(PLK1), in patients with gastrointestinal neuroendocrine tumors (GI-NET)</article-title><source>Pancreas</source><year>2016</year><volume>45</volume><fpage>475</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000000615</pub-id></element-citation></ref><ref id="B96-vaccines-09-00359"><label>96.</label><element-citation publication-type="gov"><article-title>Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02191878">https://clinicaltrials.gov/ct2/show/NCT02191878</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B97-vaccines-09-00359"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Dika</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Modiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freilich</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>An open-label, multicenter, phase I, dose escalation study with phase ii expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma</article-title><source>Oncology</source><year>2019</year><volume>24</volume><fpage>747</fpage><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0838</pub-id><pub-id pub-id-type="pmcid">PMC6656521</pub-id><pub-id pub-id-type="pmid">30598500</pub-id></element-citation></ref><ref id="B98-vaccines-09-00359"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolcher</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Patnaik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasco</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Fielman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janisch</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.D.</given-names></name><etal/></person-group><article-title>Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><elocation-id>11006</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2015.33.15_suppl.11006</pub-id></element-citation></ref><ref id="B99-vaccines-09-00359"><label>99.</label><element-citation publication-type="gov"><article-title>Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients with Hepatocellular Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02314052">https://clinicaltrials.gov/ct2/show/NCT02314052</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B100-vaccines-09-00359"><label>100.</label><element-citation publication-type="gov"><article-title>Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients with Solid Tumors, Multiple Myeloma, or Lymphoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT021105639">https://clinicaltrials.gov/ct2/show/NCT021105639</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B101-vaccines-09-00359"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>R.</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Baze</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Rodriguez-Aguayo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Lopez-Berestein</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)</article-title><source>Mol. Cancer Ther.</source><year>2017</year><volume>16</volume><fpage>1114</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0541</pub-id><pub-id pub-id-type="pmid">28265009</pub-id><pub-id pub-id-type="pmcid">PMC5457703</pub-id></element-citation></ref><ref id="B102-vaccines-09-00359"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozcan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ozpolat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lopez-Berestein</surname><given-names>G.</given-names></name></person-group><article-title>Preclinical and clinical development of siRNA-based therapeutics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>87</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.01.007</pub-id><pub-id pub-id-type="pmid">25666164</pub-id><pub-id pub-id-type="pmcid">PMC4504743</pub-id></element-citation></ref><ref id="B103-vaccines-09-00359"><label>103.</label><element-citation publication-type="gov"><article-title>EphA2 siRNA in Treating Patients with Advanced or Recurrent Solid Tumors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01591356">https://clinicaltrials.gov/ct2/show/NCT01591356</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B104-vaccines-09-00359"><label>104.</label><element-citation publication-type="gov"><article-title>Study of Safety and Tolerability of DCR HBVS</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03772249">https://clinicaltrials.gov/ct2/show/NCT03772249</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B105-vaccines-09-00359"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGoron</surname><given-names>A.J.</given-names></name></person-group><article-title>Perspectives on the future of nanomedicine to impact patients: An analysis of US Federal Funding and interventional clinical trials</article-title><source>Bioconjugate Chem.</source><year>2020</year><volume>31</volume><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.9b00818</pub-id><pub-id pub-id-type="pmid">31922742</pub-id></element-citation></ref><ref id="B106-vaccines-09-00359"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervantes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alsina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Falzone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cehelsky</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><elocation-id>3025</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2011.29.15_suppl.3025</pub-id></element-citation></ref><ref id="B107-vaccines-09-00359"><label>107.</label><element-citation publication-type="gov"><article-title>Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01158079">https://www.clinicaltrials.gov/ct2/show/NCT01158079</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-28">(accessed on 28 January 2021)</date-in-citation></element-citation></ref><ref id="B108-vaccines-09-00359"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Do</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Stemmer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Maurice-Dror</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zacharek</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36&#947;, for intratumoral (iTu) injection alone and in combination with durvalumab</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><elocation-id>3092</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.3092</pub-id></element-citation></ref><ref id="B109-vaccines-09-00359"><label>109.</label><element-citation publication-type="gov"><article-title>Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients with Advanced Malignancies</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03739931">https://clinicaltrials.gov/ct2/show/NCT03739931</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B110-vaccines-09-00359"><label>110.</label><element-citation publication-type="gov"><article-title>Dose Escalation and Efficacy Study of mRNA 2416 for Intratumoral Injection Alone and in Combination with Durvalumab for Patients With Advanced Malignancies</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/history/NCT03323398.">https://clinicaltrials.gov/ct2/history/NCT03323398.</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-10">(accessed on 10 January 2021)</date-in-citation></element-citation></ref><ref id="B111-vaccines-09-00359"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kibitel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alas</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8242;Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gerstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilchrest</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ichihashi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Enzyme therapy of xeroderma pigmentosum: Safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme</article-title><source>Photodermatol. Photoimmunol. Photomed.</source><year>1996</year><volume>12</volume><fpage>122</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0781.1996.tb00188.x</pub-id><pub-id pub-id-type="pmid">8956362</pub-id></element-citation></ref><ref id="B112-vaccines-09-00359"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadelka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dahari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ciupe</surname><given-names>S.M.</given-names></name></person-group><article-title>Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-80594-6</pub-id><pub-id pub-id-type="pmid">33420293</pub-id><pub-id pub-id-type="pmcid">PMC7794570</pub-id></element-citation></ref><ref id="B113-vaccines-09-00359"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ElBagoury</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tolba</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Jabbar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elagouz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Aktham</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>A.</given-names></name></person-group><article-title>The find of COVID-19 vaccine: Challenges and opportunities</article-title><source>J. Infect. Public Health</source><year>2021</year><volume>14</volume><fpage>389</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2020.12.025</pub-id><pub-id pub-id-type="pmid">33647555</pub-id><pub-id pub-id-type="pmcid">PMC7773313</pub-id></element-citation></ref><ref id="B114-vaccines-09-00359"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Riel</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Next-generation vaccine platforms for COVID-19</article-title><source>Nat. Mater.</source><year>2020</year><volume>19</volume><fpage>810</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0746-0</pub-id><pub-id pub-id-type="pmid">32704139</pub-id></element-citation></ref><ref id="B115-vaccines-09-00359"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koirala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Khatami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Britton</surname><given-names>P.N.</given-names></name></person-group><article-title>Vaccines for COVID-19: The current state of play</article-title><source>Paediatr. Respir. Rev.</source><year>2020</year><volume>35</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.prrv.2020.06.010</pub-id><pub-id pub-id-type="pmid">32653463</pub-id><pub-id pub-id-type="pmcid">PMC7301825</pub-id></element-citation></ref><ref id="B116-vaccines-09-00359"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name></person-group><article-title>Development of vaccines for SARS-CoV-2</article-title><source>F1000Research</source><year>2020</year><volume>9</volume><pub-id pub-id-type="doi">10.12688/f1000research.25998.1</pub-id><pub-id pub-id-type="pmcid">PMC7431966</pub-id><pub-id pub-id-type="pmid">32850116</pub-id></element-citation></ref><ref id="B117-vaccines-09-00359"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#8212;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B118-vaccines-09-00359"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy</article-title><source>Biomater. Sci.</source><year>2020</year><volume>8</volume><fpage>1101</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1039/C9BM01564G</pub-id><pub-id pub-id-type="pmid">31793928</pub-id></element-citation></ref><ref id="B119-vaccines-09-00359"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name></person-group><article-title>Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3167</fpage><lpage>3178</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id><pub-id pub-id-type="pmid">31047671</pub-id></element-citation></ref><ref id="B120-vaccines-09-00359"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>S.K.M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title><source>Trends Pharmacol. Sci.</source><year>2017</year><volume>38</volume><fpage>771</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id><pub-id pub-id-type="pmid">28668223</pub-id></element-citation></ref><ref id="B121-vaccines-09-00359"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Tomai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>M.J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>New horizons in adjuvants for vaccine development</article-title><source>Curr. Opin. Immunol.</source><year>2020</year><volume>65</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.08.008</pub-id><pub-id pub-id-type="pmid">33038865</pub-id><pub-id pub-id-type="pmcid">PMC7542129</pub-id></element-citation></ref><ref id="B122-vaccines-09-00359"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theobald</surname><given-names>N.</given-names></name></person-group><article-title>Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine</article-title><source>Drug Discov. Today</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.drudis.2020.06.020</pub-id><pub-id pub-id-type="pmcid">PMC7313501</pub-id><pub-id pub-id-type="pmid">32592866</pub-id></element-citation></ref><ref id="B123-vaccines-09-00359"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title><source>Nat. Nanotechnol.</source><year>2020</year><volume>15</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id></element-citation></ref><ref id="B124-vaccines-09-00359"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Lodaya</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G.</given-names></name></person-group><article-title>The continued advance of vaccine adjuvants&#8212;&#8220;We can work it out&#8221;</article-title><source>Semin. Immunol.</source><year>2020</year><volume>50</volume><elocation-id>101426</elocation-id><pub-id pub-id-type="doi">10.1016/j.smim.2020.101426</pub-id><pub-id pub-id-type="pmid">33257234</pub-id></element-citation></ref><ref id="B125-vaccines-09-00359"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Fukase</surname><given-names>K.</given-names></name></person-group><article-title>Recent advances in self-adjuvanting glycoconjugate vaccines</article-title><source>Drug Discov. Today Technol.</source><year>2020</year><comment>in press</comment><pub-id pub-id-type="doi">10.1016/j.ddtec.2020.11.006</pub-id><pub-id pub-id-type="pmid">34895656</pub-id></element-citation></ref><ref id="B126-vaccines-09-00359"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderluzzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Cunliffe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Veggi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ferlenghi</surname><given-names>I.</given-names></name><name name-style="western"><surname>O&#8242;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name></person-group><article-title>Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses</article-title><source>J. Control Release</source><year>2020</year><volume>330</volume><fpage>933</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.066</pub-id><pub-id pub-id-type="pmid">33152394</pub-id></element-citation></ref><ref id="B127-vaccines-09-00359"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shih</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>C.Y.</given-names></name></person-group><article-title>Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines</article-title><source>Biomed. J.</source><year>2020</year><volume>43</volume><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2020.05.021</pub-id><pub-id pub-id-type="pmid">32532623</pub-id><pub-id pub-id-type="pmcid">PMC7260535</pub-id></element-citation></ref><ref id="B128-vaccines-09-00359"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capua</surname><given-names>I.</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mattevi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Toward nanotechnology-enabled approaches against the COVID-19 pandemic</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>6383</fpage><lpage>6406</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c03697</pub-id><pub-id pub-id-type="pmid">32519842</pub-id></element-citation></ref><ref id="B129-vaccines-09-00359"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>clinical translation of nanomedicine and biomaterials for cancer immunotherapy: Progress and perspectives</article-title><source>Adv. Ther.</source><year>2020</year><elocation-id>1900215</elocation-id><pub-id pub-id-type="doi">10.1002/adtp.201900215</pub-id></element-citation></ref><ref id="B130-vaccines-09-00359"><label>130.</label><element-citation publication-type="gov"><article-title>Evaluation of the Safety and Tolerability of, i.v. Administration of a Cancer Vaccine in Patients with Advanced Melanoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02410733">https://clinicaltrials.gov/ct2/show/NCT02410733</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B131-vaccines-09-00359"><label>131.</label><element-citation publication-type="gov"><article-title>Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination With Pembrolizumab in Subjects with Unresectable Solid Tumors (KEYNOTE-603)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03313778">https://clinicaltrials.gov/ct2/show/NCT03313778</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B132-vaccines-09-00359"><label>132.</label><element-citation publication-type="gov"><article-title>An Efficacy Study of Adjuvant Treatment with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients with High-Risk Melanoma (KEYNOTE-942)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03897881">https://clinicaltrials.gov/ct2/show/NCT03897881</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B133-vaccines-09-00359"><label>133.</label><element-citation publication-type="gov"><article-title>Tetravalent RNA-Lipoplex Cancer Vaccine (Concept Id: C4053753)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/medgen/882172">https://www.ncbi.nlm.nih.gov/medgen/882172</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-02-15">(accessed on 15 February 2021)</date-in-citation></element-citation></ref><ref id="B134-vaccines-09-00359"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hefesha</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature18300</pub-id><pub-id pub-id-type="pmid">27281205</pub-id></element-citation></ref><ref id="B135-vaccines-09-00359"><label>135.</label><element-citation publication-type="web"><article-title>Stimuvax&#8212;Investigational Therapeutic Cancer Vaccine</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsarena.com/projects/stimuvax/">https://www.clinicaltrialsarena.com/projects/stimuvax/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-04-02">(accessed on 2 April 2021)</date-in-citation></element-citation></ref><ref id="B136-vaccines-09-00359"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKay</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Samnuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Penn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouton</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Polra</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><elocation-id>3523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17409-9</pub-id><pub-id pub-id-type="pmid">32647131</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id></element-citation></ref><ref id="B137-vaccines-09-00359"><label>137.</label><element-citation publication-type="web"><article-title>Vaccines&#8211;COVID19 Vaccine Tracker Home Page</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid19.trackvaccines.org/vaccines/">https://covid19.trackvaccines.org/vaccines/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B138-vaccines-09-00359"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Madou</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kalra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez-Chapa</surname><given-names>S.O.</given-names></name></person-group><article-title>Nanotechnology for COVID-19: Therapeutics and Vaccine Research</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>7760</fpage><lpage>7782</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c04006</pub-id><pub-id pub-id-type="pmid">32571007</pub-id></element-citation></ref><ref id="B139-vaccines-09-00359"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Current status of potential therapeutic candidates for the COVID-19 crisis</article-title><source>Brain Behav. Immun.</source><year>2020</year><volume>87</volume><fpage>59</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.04.046</pub-id><pub-id pub-id-type="pmid">32334062</pub-id><pub-id pub-id-type="pmcid">PMC7175848</pub-id></element-citation></ref><ref id="B140-vaccines-09-00359"><label>140.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>(WHO) T.W.H.O</collab></person-group><article-title>Draft Landscape of COVID-19 Candidate Vaccines</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-02">(accessed on 2 December 2020)</date-in-citation></element-citation></ref><ref id="B141-vaccines-09-00359"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maurus</surname><given-names>D.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2814-7</pub-id><pub-id pub-id-type="pmid">32998157</pub-id></element-citation></ref><ref id="B142-vaccines-09-00359"><label>142.</label><element-citation publication-type="gov"><article-title>A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04380701">https://clinicaltrials.gov/ct2/show/NCT04380701</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B143-vaccines-09-00359"><label>143.</label><element-citation publication-type="gov"><article-title>Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04368728">https://clinicaltrials.gov/ct2/show/NCT04368728</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B144-vaccines-09-00359"><label>144.</label><element-citation publication-type="gov"><article-title>Pfizer-BioNTech COVID-19 Vaccine</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine">https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B145-vaccines-09-00359"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name></person-group><article-title>COVID-19 Vaccine: A comprehensive status report</article-title><source>Virus Res.</source><year>2020</year><volume>288</volume><elocation-id>198114</elocation-id><pub-id pub-id-type="doi">10.1016/j.virusres.2020.198114</pub-id><pub-id pub-id-type="pmid">32800805</pub-id><pub-id pub-id-type="pmcid">PMC7423510</pub-id></element-citation></ref><ref id="B146-vaccines-09-00359"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation></ref><ref id="B147-vaccines-09-00359"><label>147.</label><element-citation publication-type="gov"><article-title>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461">https://clinicaltrials.gov/ct2/show/NCT04283461</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B148-vaccines-09-00359"><label>148.</label><element-citation publication-type="gov"><article-title>Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04405076?term=moderna&amp;cond=covid-19&amp;draw=2">https://clinicaltrials.gov/ct2/show/NCT04405076?term=moderna&amp;cond=covid-19&amp;draw=2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B149-vaccines-09-00359"><label>149.</label><element-citation publication-type="gov"><article-title>A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&amp;cond=covid-19&amp;draw=5">https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&amp;cond=covid-19&amp;draw=5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B150-vaccines-09-00359"><label>150.</label><element-citation publication-type="web"><article-title>Moderna COVID Vaccine Becomes Second to Get US Authorization</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-020-03593-7">https://www.nature.com/articles/d41586-020-03593-7</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B151-vaccines-09-00359"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cederna</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Rohrich</surname><given-names>R.J.</given-names></name></person-group><article-title>The race for a COVID-19 Vaccine: Current trials, novel technologies, and future directions</article-title><source>Plast. Reconstr. Surg. Glob. Open</source><year>2020</year><volume>8</volume><elocation-id>e3206</elocation-id><pub-id pub-id-type="pmid">33173705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GOX.0000000000003206</pub-id><pub-id pub-id-type="pmcid">PMC7647601</pub-id></element-citation></ref><ref id="B152-vaccines-09-00359"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>D.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>S.</given-names></name></person-group><article-title>Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women (ISRCTN17072692)</article-title><source>BioMedCentral</source><year>2020</year><pub-id pub-id-type="doi">10.1186/isrctn17072692</pub-id></element-citation></ref><ref id="B153-vaccines-09-00359"><label>153.</label><element-citation publication-type="gov"><article-title>Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04480957">https://clinicaltrials.gov/ct2/show/NCT04480957</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B154-vaccines-09-00359"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kotla</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Bohara</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rochev</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bayry</surname><given-names>J.</given-names></name></person-group><article-title>Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections</article-title><source>Nano Today</source><year>2021</year><volume>36</volume><elocation-id>101051</elocation-id><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101051</pub-id><pub-id pub-id-type="pmid">33519949</pub-id><pub-id pub-id-type="pmcid">PMC7834523</pub-id></element-citation></ref><ref id="B155-vaccines-09-00359"><label>155.</label><element-citation publication-type="web"><article-title>Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies</article-title><day>25</day><month>1</month><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.globenewswire.com/news-release/2020/10/15/2109121/0/en/Sanofi-and-Translate-Bio-mRNA-COVID-19-vaccine-candidate-induced-high-antibody-levels-in-preclinical-studies.html">https://www.globenewswire.com/news-release/2020/10/15/2109121/0/en/Sanofi-and-Translate-Bio-mRNA-COVID-19-vaccine-candidate-induced-high-antibody-levels-in-preclinical-studies.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B156-vaccines-09-00359"><label>156.</label><element-citation publication-type="web"><article-title>Sanofi, Translate Bio Start Phase 1:2 Clinical Trial Of MRNA COVID-19 Vaccine Candidate</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nasdaq.com/articles/sanofi-translate-bio-start-phase-1-2-clinical-trial-of-mrna-covid-19-vaccine-candidate">https://www.nasdaq.com/articles/sanofi-translate-bio-start-phase-1-2-clinical-trial-of-mrna-covid-19-vaccine-candidate</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-12">(accessed on 12 March 2021)</date-in-citation></element-citation></ref><ref id="B157-vaccines-09-00359"><label>157.</label><element-citation publication-type="web"><article-title>CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.precisionnanosystems.com/news-room/detail/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine">https://www.precisionnanosystems.com/news-room/detail/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B158-vaccines-09-00359"><label>158.</label><element-citation publication-type="web"><article-title>Development of IMV&#8217;s DPX-COVID-19 Vaccine Progresses Apace</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/">https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B159-vaccines-09-00359"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>A thermostable mRNA vaccine against COVID-19</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1271</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.024</pub-id><pub-id pub-id-type="pmid">32795413</pub-id><pub-id pub-id-type="pmcid">PMC7377714</pub-id></element-citation></ref><ref id="B160-vaccines-09-00359"><label>160.</label><element-citation publication-type="web"><article-title>A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Preliminary Immunogenicity of Different Doses of a SARS-CoV-2 mRNA Vaccine in Population Aged 18-59 Years and 60 Years and Above</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=55524">http://www.chictr.org.cn/showprojen.aspx?proj=55524</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-25">(accessed on 25 January 2021)</date-in-citation></element-citation></ref><ref id="B161-vaccines-09-00359"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00392-7</pub-id><pub-id pub-id-type="pmid">32801356</pub-id><pub-id pub-id-type="pmcid">PMC7429369</pub-id></element-citation></ref><ref id="B162-vaccines-09-00359"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shibuya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Munakata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Omata</surname><given-names>D.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses</article-title><source>Vaccines</source><year>2020</year><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030433</pub-id><pub-id pub-id-type="pmcid">PMC7565178</pub-id><pub-id pub-id-type="pmid">32756368</pub-id></element-citation></ref><ref id="B163-vaccines-09-00359"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swaminathan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thoryk</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Meschino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Celano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gindy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Bett</surname><given-names>A.J.</given-names></name></person-group><article-title>A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.10.132</pub-id><pub-id pub-id-type="pmid">26555351</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-09-00359-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(<bold>a</bold>) Structure of FDA approved Doxil<sup>&#174;</sup> and Onpattro<sup>&#174;</sup> (patisiran) nanoparticles&#8212;the first FDA approved liposome and lipid nanoparticle, Created in BioRender.com; (<bold>b</bold>) chemical structure of the lipids inDoxil<sup>&#174;</sup> and Onpattro<sup>&#174;</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g001.jpg"/></fig><fig id="vaccines-09-00359-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Schematic representation of the five categories of lipid-based nanoparticles: Liposomes, niosomes, transfersomes, solid lipid nanoparticles (SLNs) and the nanostructured lipid carriers (NLCs). Created in BioRender.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g002.jpg"/></fig><fig id="vaccines-09-00359-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Impact of pH on the protonation and structure of charge-reversible lipid-based nanoparticles encapsulating siRNA. These lipid nanoparticles become positive charge at pH of 6.0, neutral at pH of 7.4 and a negative charge at pH of 8.0 gained due to an ionizable lipid of di-oleoylglycerophosphate-diethylenediamine conjugate (DOP-DEDA). Used with permission from [<xref rid="B48-vaccines-09-00359" ref-type="bibr">48</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g003.jpg"/></fig><fig id="vaccines-09-00359-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Chemical structure of targeting lipids? DSPG (1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DMPG (1,2-dimyristoyl-sn-glycero-3-phosphoglycerol), SPH (sphingomyelin), DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), EPC (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine), EPG (L-&#945;-phosphatidylglycerol), DPPC (dipalmitoylphosphatidylcholine), DPPG ([3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl]hexadecanoate, cholesterol, Tween 80 (2-[2-[3,5-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (E)-octadec-9-enoate), Tween 20 (2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl dodecanoate), ATX-1 (one of the LUNAR lipids of Arturus Therapeutics, Inc., San Diego, CA, USA) and DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g004.jpg"/></fig><fig id="vaccines-09-00359-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Chemical structures of the most common ionizable cationic lipids: 1,2-dioleoyl-3-dimethylaminopropane (DODAP), 1,2-dilinoleoyl-3-dimethylaminopropane, 1,2- dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl- 4-dimethylaminomethyl-[<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>]-dioxolane (DLin-K-DMA) and 2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[<xref rid="B1-vaccines-09-00359" ref-type="bibr">1</xref>,<xref rid="B3-vaccines-09-00359" ref-type="bibr">3</xref>]-dioxolane (DLin-KC2-DMA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g005.jpg"/></fig><fig id="vaccines-09-00359-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Immunomodulation strategies to improve cancer immunotherapy in nanomedicines: Nanomedicine was designed to induce immunogenic cell death, to promote antitumor immunity (cancer vaccination), to modulate immune cells, to activate innate immunity, to inhibit soluble immunosuppressive factors, to alternate tumor matrix, to engineer lymphocyte and normalize vessel [<xref rid="B129-vaccines-09-00359" ref-type="bibr">129</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00359-g006.jpg"/></fig><table-wrap id="vaccines-09-00359-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of main characteristics of common lipid-based nanoparticles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Particle Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Shape/<break/>Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preparation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drawbacks</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phospholipid, cholesterol, essential oils [<xref rid="B31-vaccines-09-00359" ref-type="bibr">31</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical, 10&#8211;1000 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanical dispersion, Solvent dispersion, Detergent removal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug protection, controlled release, solubility enhancement for hydrophobic therapeutic agents, high bioavailability and biodistribution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not crossing the stratum corneum barrier, rigid structure [<xref rid="B31-vaccines-09-00359" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Niosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol, non-ionic surfactants [<xref rid="B31-vaccines-09-00359" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical<break/>, 10&#8211;1000 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sonication, micro-fluidization, ether injection method, bubble method</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting to specific sites, enhanced stability and longer shelf life than liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug leakage, particle aggregation [<xref rid="B30-vaccines-09-00359" ref-type="bibr">30</xref>], high production costs and the scarcity of FDA-approved polymers [<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transfersomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phospholipids and edge activators [<xref rid="B31-vaccines-09-00359" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical<break/>, &lt;300 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rotary film evaporation, reverse-phase evaporation, vortexing sonication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher penetration, good stability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highly prone to oxidative degradation, high cost and impurity of natural phospholipids</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid lipid nanoparticles (SLNs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid fats, surfactants [<xref rid="B32-vaccines-09-00359" ref-type="bibr">32</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spherical,<break/>50&#8211;1000 nm</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Micro emulsification, sonication, high pressure homogenization [<xref rid="B27-vaccines-09-00359" ref-type="bibr">27</xref>,<xref rid="B33-vaccines-09-00359" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biocompatible and biodegradable ingredients, high cell uptake, good protection of drugs in acidic pH, long shelf life, ease of drug entrapment [<xref rid="B32-vaccines-09-00359" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelling tendency [<xref rid="B29-vaccines-09-00359" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanostructured lipid carriers (NLCs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid and liquid lipids (fats and oils), surfactants [<xref rid="B32-vaccines-09-00359" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All SLN&#8217;s advantages but higher drug encapsulation, more sustainable drug release, better diuretic activity and fewer drug lost within storage time [<xref rid="B32-vaccines-09-00359" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optimization required of the ratio of solid/liquid lipids</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-09-00359-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t002_Table 2</object-id><label>Table 2</label><caption><p>Overview of the approved liposomes in EU and US.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Initial Approval Time</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Commercial Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Liposome Components</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC:<break/>cholesterol:<break/>DSPE-PEG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast neoplasms; multiple myeloma; ovarian neoplasms; Kaposi&#8217;s sarcoma</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abelcet<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DMPC:DMPG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Life-threatening fungal infections.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DaunoXome<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC: Cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer advanced HIV-associated Kaposi&#8217;s sarcoma</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AmBisome<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC:DSPG, cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visceral leishmaniasis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DepoCyt<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOPC:DPPG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neoplastic meningitis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curosurf<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SP-B and SP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A natural surfactant of porcine lungs [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RDS in premature infants</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AmBisome<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC:DSPG, cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cryptococcal Meningitis in AIDS Patients</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocet<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPC: Cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast neoplasms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visudyne<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Verteporfin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPG:DMPC [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub foveal choroidal neovascularization</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DepoDur<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morphine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOPC:DPPG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain relief</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marqibo<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vincristine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPH: Cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Philadelphia chromosome-negative acute lymphoblastic leukemia [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mepact<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mifamurtide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOPC:DOPS [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osteosarcoma</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exparel<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupivacaine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DEPC: DPPG: Cholesterol:<break/>Tricaprylin [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anesthetic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marqibo<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vincristine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPH: Cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematologic malignancies and solid tumors [<xref rid="B7-vaccines-09-00359" ref-type="bibr">7</xref>,<xref rid="B71-vaccines-09-00359" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipodox<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC: Cholesterol:<break/>DSPE-PEG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast neoplasms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onivyde<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC: Cholesterol:<break/>DSPE-PEG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic pancreatic cancer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC: Cholesterol: DSPE-PEG [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast neoplasms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nocita<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupivacaine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DEPC: DPPG: Cholesterol:<break/>Tricaprylin [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anesthetic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vyxeos<sup>&#174;</sup><break/>(CPX-351)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin Cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC: DSPG:<break/>Cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ArikayceTM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amikacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPC: Cholesterol [<xref rid="B6-vaccines-09-00359" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycobacterium avium complex lung disease</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LipoplatinTM<break/>NanoplatinTM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPG: soy PC: MPEG-DSPE: Cholesterol [<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic cancer<break/>Lung cancer</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-09-00359-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t003_Table 3</object-id><label>Table 3</label><caption><p>Liposomal formulations in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug &amp; Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug/Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome Encapsulated Mitoxantrone (LEM)<break/>INSYS Therapeutics Inc (Phoenix, AZ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitoxantrone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00024492">NCT00024492</ext-link><break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-CKD602<break/>University of Pittsburgh<break/>ALZA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CKD-602</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00177281">NCT00177281</ext-link> <break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Malignancies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan Liposomes Injection (TLI)<break/>Spectrum Pharmaceuticals, Inc (Henderson, NV, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00765973">NCT00765973</ext-link><break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small Cell Lung Cancer<break/>Ovarian Cancer<break/>Solid Tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-vaccines-09-00359" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INX-0076<break/>Inex Pharmaceuticals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced solid tumours</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLD-1<break/>Swiss group for clinical cancer research</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1<break/>Recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03387917">NCT03387917</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Solid Tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-vaccines-09-00359" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LEP-ETU<break/>INSYS Therapeutics Inc (Phoenix, AZ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00080418">NCT00080418</ext-link><break/>Completed<break/>Phase 2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01190982">NCT01190982</ext-link><break/>Completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00100139">NCT00100139</ext-link><break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced cancer (Neoplasm)<break/>Metastatic Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>,<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBP-426<sup>&#174;</sup><break/>Mebiopharm Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxaliplatin / Transferrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00964080">NCT00964080</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid Tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-vaccines-09-00359" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MM-302 <break/>Merrimack</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin / Antibody fragment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2<break/>Terminated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-vaccines-09-00359" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LiPlaCis<break/>Oncology Venture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01861496">NCT01861496</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1: Advanced or Refractory Solid Tumours<break/>Phase 2: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPI-77<break/>NYU Langone Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00004083">NCT00004083</ext-link><break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OSI-211 <break/>Astellas Pharma Inc, OSI Pharmaceuticals (Farmingdale, NY, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lurtotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00046787">NCT00046787</ext-link><break/>Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent Small Cell Lung Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>,<xref rid="B82-vaccines-09-00359" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ThermoDox<sup>&#174;</sup><break/>Celsion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin / Targeted thermal therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02112656">NCT02112656</ext-link><break/>completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatocellular Carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-vaccines-09-00359" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBP-Y003<break/>Mebiopharm Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methotrexate / Transferrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-vaccines-09-00359" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBP-Y004<break/>Mebiopharm Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Docetaxel / Transferrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-vaccines-09-00359" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBP-Y005<break/>Mebiopharm Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabin / Transferrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-vaccines-09-00359" ref-type="bibr">73</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-09-00359-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t004_Table 4</object-id><label>Table 4</label><caption><p>List of RNA-encapsulated lipid nano-particles (LNPs) with indication and clinical trial information.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug and Its Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCR-MYC<break/>Dicerna Pharmaceuticals,<break/>Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogene MYC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated, Phase I, II <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02314052">NCT02314052</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02110563">NCT02110563</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors, <break/>hepatocellular Carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>,<xref rid="B99-vaccines-09-00359" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TKM-080301<break/>Arbutus Biopharma<break/>Corporation (Warminster, PA, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLK1 (polo-like kinase-1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, Phase I, II <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01262235">NCT01262235</ext-link>,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02191878">NCT02191878</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal neuroendocrine tumors, adrenocortical carcinoma tumors, advanced hepatocellular<break/>carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>,<xref rid="B94-vaccines-09-00359" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-09-00359" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-09-00359" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EphA2 siRNA<break/>M.D. Anderson Cancer Center<break/>National Cancer Institute (NCI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EphA2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting,<break/>Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01591356">NCT01591356</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Malignant Solid Neoplasm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>,<xref rid="B101-vaccines-09-00359" ref-type="bibr">101</xref>,<xref rid="B103-vaccines-09-00359" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARB-001467 <break/>Arbutus Biopharma Corporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, Phase II <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02631096">NCT02631096</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B, Chronic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRO-040201 <break/>Arbutus Biopharma Corporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ApoB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated, Phase I (Potential for immune<break/>stimulation to interfere with further dose escalation.)<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00927459">NCT00927459</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALN-PCS02 <break/>Alnylam Pharmaceuticals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCSK9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, Phase I <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01437059">NCT01437059</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated LDL-cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND-L02-s0201 <break/>Bristol-Myers Sqyubb Pharmaceuticals</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSP47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, Phase I <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02227459">NCT02227459</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic fibrosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-09-00359" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARC-520<break/>Arrowhead Pharmaceuticals and ICON Clinical Research</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated,<break/>Phase 2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02065336">NCT02065336</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Hepatitis B Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-vaccines-09-00359" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCR HBVS<break/>Dicerna Pharmaceuticals, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting,<break/>Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03772249">NCT03772249</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B, Chronic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-vaccines-09-00359" ref-type="bibr">23</xref>,<xref rid="B104-vaccines-09-00359" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALN-VSP02 Lipid Nanoparticle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA-KSP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed,<break/>Phase 1,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01158079">NCT01158079</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer- Solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-vaccines-09-00359" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-09-00359" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-09-00359" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-2752 Lipid Nanoparticle<break/>Moderna Tx. Inc. (Cambridge, MA, USA) and AstraZeneca (Cambridge, UK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OX40L T cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting,<break/>Phase 1<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer- various</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-vaccines-09-00359" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-09-00359" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-2416 Lipid Nanoparticle<break/>ModernaTX, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OX40L T cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting,<break/>Phase 1&#8211;2,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03323398">NCT03323398</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer- Solid Tumor,Lymphoma, Ovarian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-vaccines-09-00359" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal T4N5 Lotion<break/>National Cancer Institute (NCI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">a prokaryotic DNA repair enzyme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed<break/>Phase 2<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00089180">NCT00089180</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The Recurrence of Nonmelanoma Skin Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-vaccines-09-00359" ref-type="bibr">111</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="vaccines-09-00359-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t005_Table 5</object-id><label>Table 5</label><caption><p>Clinical trial information of LNPs for cancer vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipo-MERIT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioNTech RNA Pharmaceuticals GmbH<break/>Phase 1: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link> (*) [<xref rid="B130-vaccines-09-00359" ref-type="bibr">130</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer (melanoma)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-4157</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ModernaTX, Inc. and Merck Sharp &amp; Dohme Corp.<break/>Phase 1: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03313778">NCT03313778</ext-link> (*) [<xref rid="B131-vaccines-09-00359" ref-type="bibr">131</xref>]<break/>Phase 2: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03897881">NCT03897881</ext-link> (*) [<xref rid="B132-vaccines-09-00359" ref-type="bibr">132</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer<break/>(bladder carcinoma, melanoma and non-small-cell lung carcinoma (NSCLC))</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimuvax <break/>(L-BLP-25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMD Serono &amp; Merck KGaA, Darmstadt, Germany.<break/>Phase 3: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00409188">NCT00409188</ext-link> (*)<break/>Terminated [<xref rid="B72-vaccines-09-00359" ref-type="bibr">72</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small-cell lung cancer</td></tr></tbody></table><table-wrap-foot><fn><p>(*) ClinicalTrials.gov identifier.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-09-00359-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00359-t006_Table 6</object-id><label>Table 6</label><caption><p>List of the COVID-19 vaccines using LNPs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic toggle="yes">Approved by FDA</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-1273</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ModernaTX, Inc.<break/>Phase 1: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link> (*)<break/>Phase 2: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link> (*)<break/>Phase 3: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link> (*)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-vaccines-09-00359" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-09-00359" ref-type="bibr">128</xref>,<xref rid="B147-vaccines-09-00359" ref-type="bibr">147</xref>,<xref rid="B150-vaccines-09-00359" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162b2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioNTech SE and Pfizer<break/>Phase 1/2: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link> (*)<break/>Phase 2/3: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link> (*)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-vaccines-09-00359" ref-type="bibr">144</xref>]</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic toggle="yes">In clinical evaluation stage</italic></bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BNT162a1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BioNTech SE and Pfizer<break/>Phase 1/2: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link> (*)<break/>Phase 2/3: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link> (*)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B138-vaccines-09-00359" ref-type="bibr">138</xref>,<xref rid="B141-vaccines-09-00359" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BNT162b1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT162c2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARCT-021 (mRNA Lunar-Cov19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arcturus Therapeutics and Duke-NUS<break/>Phase 1/2: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-vaccines-09-00359" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVAC1 (LNP-nCoVsaRNA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Imperial College London<break/>Phase 1: ISRCTN17072692 (*)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B151-vaccines-09-00359" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-09-00359" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChulaCov19 mRNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chula Vaccine Research Center/University of Pennsylvania<break/>Phase 1: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566276">NCT04566276</ext-link> (*)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-VoV-2 mRNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shulan (Hangzhou) Hospital; Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region <break/>Phase 1: ChiCTR2000034112 (*)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-vaccines-09-00359" ref-type="bibr">160</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D614G variant LNP-encapsulated mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Globe Biotech Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic toggle="yes">In pre-clinical stage</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-encapsulated mRNA encoding S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max-Planck-Institute of Colloids and Interfaces</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translate Bio/Sanofi Pasteur</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CanSino Biologics/Precision NanoSystems</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-encapsulated mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University of Tokyo/Daiichi-Sankyo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide antigens formulated in LNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMV Inc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LNP-encapsulated mRNA encoding RBD</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fudan University/ Shanghai JiaoTong University/RNACure Biopharma</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B159-vaccines-09-00359" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LNP-encapsulated mRNA encoding the full-length wild-type (WT) S</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B161-vaccines-09-00359" ref-type="bibr">161</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-encapsulated mRNA cocktail encoding VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00359" ref-type="bibr">140</xref>,<xref rid="B161-vaccines-09-00359" ref-type="bibr">161</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>(*) ClinicalTrials.gov indentifier.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>